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Summary in Japanese 
	 人工的な構造を持つペプチドライブラリーの作製が、近年、創薬分野におい
て注目を集めている。特に、バクテリオファージに融合されたランダム化ペプ
チドに対して化学修飾を行うことで、ハイブリッド分子ライブラリーの作製が
試みられている。しかしながら、既存の M13 ファージに対する化学修飾法では
副反応や大腸菌感染能が低下するなどの問題が存在した。そこで、T7 ファージ
提示ペプチドのチオエーテル化を試み、T7 ファージ提示ペプチド選択的なワン
ポット化学修飾を世界で初めて達成した。さらに、化学修飾した T7 ファージは
大腸菌への感染能を損なわなかった。この技術を用いて異なる構造的特徴を持
つハイブリッド分子ライブラリーを 3 種類構築し、任意の標的タンパク質に結
合する分子のセレクション・機能解析を行った。 
 
  
  
Preface 
 
Since G.P. Smith reported the concept of phage display in 1985, the 
technique has been used as a powerful tool for construction of a peptide 
library. Currently, the phage display is applied for construction of a 
non-natural peptide library: peptide-artificial molecule hybrid library is 
constructed via post-translational chemical modifications of 
phage-displayed peptides. 
 
Chapter 1 reviews features of two major phage display systems. In 
particular, sequence bias problems and practical tips on the library 
construction are discussed in detail. 
 
The fist half of chapter 2 focuses on establishment of a novel method to 
construct the peptide-artificial molecule hybrid library. Here, I found that 
bacteriophage T7-displayed peptides are modifiable in a simplest method 
without side reaction and infectivity loss, whereas the site-specific 
modification of bacteriophage M13-displayed peptides are ultimately 
difficult. 
 
From the latter half of the chapter 2 to chapter 4 focuses on construction 
of different kinds of the hybrid library and on screening of target-specific 
binders: In the chapter 2, fluorophore-conjugated hybrid molecule library is 
constructed, and glutathione S-transferase-specific binders are obtained. In 
the chapter 3, drug-like molecule-conjugated hybrid molecule library is 
constructed, and streptavidin-specific binders are obtained. In the chapter 4, 
crown ether-like macrocyclic library is constructed so that 
oligoethyleneglycol moiety has a good biocompatibility. Also, a novel 
binder against Hsp90, which is a drug target in cancer therapy, is obtained.   
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CHAPTER 1 
 
Comparison of T7 and M13 systems in 
phage display 
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n Abstract 
 
Phage display technology is undoubtedly a powerful tool for affinity selection of 
target-specific peptide. Commercially available pre-made phage libraries allow us to 
take screening in the easiest way. On the other hand, construction of a custom phage 
library seems to be inaccessible, because several practical tips are absent in instructions. 
This chapter focuses on what should be born in mind for beginners using commercially 
available cloning kits (i.e., Ph.D. with type 3 vector and T7Select systems for M13 and 
T7 phage, respectively). In the M13 system, proline or basic amino acids (especially, 
Arg) should be avoided at the N-terminus of peptide fused to gp3. In both systems, 
peptides containing odd number(s) of cysteine(s) should be designed with caution. Also, 
DNA sequencing of a constructed library before biopanning is highly recommended for 
finding unexpected bias. 
(C) 2014 Keisuke Fukunaga, All Rights Reserved. 
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■	 1.1 Introduction 
 
Phage display technology was born in 1985 when George Smith reported that 
foreign peptide could be displayed on the surface of filamentous bacteriophage.1 Today, 
the phage display is a versatile tool for finding specific interactions between 
randomized library peptides/proteins on phage and target proteins, peptides, or other 
molecules. For example, it is applicable for generation of therapeutic peptides against 
cancer,2 microbe,3 novel functional protein,4 or fully humanized monoclonal antibody.5 
The advantages of the phage display technology over other selection methods (e.g., 
ribosome display) are: (i) cost of a routine is cheap. (ii) Time required for 
selection/amplification is fast. (iii) Extreme care for handling, such as RNA 
isolation/selection, is not necessary. The phage is a DNA-containing virus that infects 
bacteria, and makes many copies of the library within a very short time.6 
A phage that specifically binds a target can be selected from mixtures of billions of 
phages, propagated by in vivo amplification, and then subjected to additional rounds of 
affinity selection (Fig. 1). This whole process is so called “biopanning”.7 After multiple 
rounds of the biopanning, enrichment of target-binding phages can be assessed by 
phage titering and enzyme-linked immunosorbent assay (ELISA). Finally, the peptide 
displayed on the phage can be analyzed by DNA sequencing. 
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Figure 1. A typical procedure of the biopanning. (A) Incubation of phage library with an 
immobilized target. (B) Washing of unbound phage. (C) Elution of target-bound phage. (D) 
Amplification of the eluted phage for subsequent rounds of the biopanning. 
 
Categorization of phage display systems. 
Based on vector systems, the phage display systems can be categorized into two 
classes. One is a true phage vector system. The phage vector is often derived from 
genes encoding all phage proteins.8 The library is to be cloned as a fusion with a 
component gene, which originally exists in the phage genome. Alternatively, some 
libraries are to be inserted in the same vector as an additional fusion gene encoding a 
displaying peptide and a phage protein.9  
Another is a phagemid vector system. The phagemid is a plasmid containing both a 
phage-derived replication origin and a plasmid-derived one.10 A phage containing the 
phagemid can be generated only when phage components are secreted from bacterial 
host carrying a helper phage. In this system, two types of phages could be theoretically 
produced carrying either phagemid genome or helper-phage one. Practically, a helper 
phage with defective replication origin is used for the generation of phage proteins; 
production of the helper phage itself will be suppressed. This system yields a phage 
(C) 2014 Keisuke Fukunaga, All Rights Reserved. 
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with the wild-type protein and library-fused one on the same virion, encoded by the 
helper phage and phagemid vector, respectively. Thus, numbers of the displaying 
peptides per virion from the phagemid system are less than those from the true vector 
system. This allows us to display not only small peptides but also large proteins,11 
which is beyond the scope of this chapter. 
Among many different kinds of phages, M13 (filamentous bacteriophage) and T7 
(lytic one) are exclusively used for the phage display. The M13 phage is composed of a 
circular single-stranded DNA genome and thousands copies of major capsid proteins 
(gp8), and capped by five copies of gp3 + gp6 on one end and five copies of gp7 + gp9 
on the opposite (Fig. 2). The most widely-used M13 system is type 3. In this system, the 
peptide library is fused to the N-terminus of all five copies of the gp3. Other systems 
(e.g., type 33, type 8 etc.) are categorized by a peptide-displaying protein on the M13 
phage and numbers of peptides per virion (Table 1).12, 13  
The T7 phage is an icosahedral-shaped phage with a capsid shell that is composed 
of 415 copies of gp10, linear double-stranded DNA, and other proteins (Fig. 2).14 The 
gp10 includes two forms, gp10A (344 amino acids) and its frameshifting product, 
gp10B (397 amino acids).15 In the T7 phage display systems, peptide library is always 
fused to the C-terminus of the gp10B. Numbers of peptides per virion and maximal size 
of the peptide are determined by the vector system (Table 1).16 
 
 
Figure 2.  Structures of (A) the filamentous M13 bacteriophage, and (B) the lytic T7 
bacteriophage. 
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Table 1. Features of various systems of M13 and T7 phages. 
 
 
 
 
Table 2. Consignment services of phage display with in-house libraries. 
Company name Peptide design Peptide structure 
Creative Biolabs X10, X16, or X20 *1 linear 
Dyax Xa-C-Xb-C-Xc *1 cyclic 
Bicycle Therapeutics Xa-C-Xb-C-Xc-C-Xd *2 
cyclic with a non-natural 
linker 
X stands for any randomized amino acid.  
*1 The library was built by varying 19 aa at the randomized positions; the codon encoding Cys is 
excluded. 
*2 Bicyclic peptide library was made via thioether linkages.30 
 
 
 System Size limit 
Numbers of 
peptides per 
virion 
Presentation region 
M13 
3 unknown 5 
N-terminus to gp3 33 
No limit < 1 
3 + 3 
8 Short > 2,700 
N-terminus to gp8 88 unknown < 300 
8 + 8 No limit 100-1000 
8 + 8 unknown 
< 1 
C-terminus to gp8 
6 + 6 
No limit 
N-terminus to gp6 
6 + 6 C-terminus to gp6 
9 + 9 N-terminus to gp9 
T7 
T7Select1-1 1200 aa 
< 1 
C-terminus to gp10B 
T7Select1-2 900 aa 
T7Select10-3 1200 aa 5 - 15 
T7Select415-1 50 aa 415 
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Using pre-made phage libraries. 
For screening, using a pre-made phage library is the most convenient way. Three 
types of M13 phage libraries, consisting of random linear/cyclic heptapeptides (Ph.D.-7 
/ Ph.D.-C7C) and linear dodecapeptides (Ph.D.-12), are commercially distributable from 
New England Biolabs Inc. (NEB). Several companies have constructed in-house 
pre-made peptide libraries; they provide screening services by using their phage 
libraries, instead of distributing ones. The chemical structures and features of the 
libraries are summarized in Table 2. Creative Biolabs Inc. even accepts a service 
contract from a commercial pre-made library (e.g., Ph.D.-C7C system), a 
custom-constructed one in the company, or a hand-made one.       
 
 
Construction of custom phage library. 
Because of the limited kinds of resources, constructions of custom phage libraries 
are often performed by using kits available from NEB (Ph.D. Cloning System for M13 
phage) or Merck Millipore (T7Select Cloning Kit for T7 one).6 Although these 
instructions are well described, several practical tips are missing in both of them, which 
may lead beginners to pitfalls such as obtaining severe inherent bias of amino acid 
sequence in the randomized region. This chapter focuses on instant tips for the 
construction of peptide libraries and affinity selection by using the commercial 
resources.   
(C) 2014 Keisuke Fukunaga, All Rights Reserved. 
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n 1.2 Characteristics of Ph.D. cloning system 
 
Ph.D. cloning system is based on a type 3 vector of M13 phage encoding N-terminal 
library peptide fused to a minor coat protein, gp3.17 Because gp3 plays a critical role for 
phage infection and randomized peptides are fused in all five copies of the gp3, 
infectivity of the M13 phage can be significantly affected by a sequence of the 
displaying peptide. Moreover, secretion of the M13 phage from E. coli closely depends 
on charges, hydrophilicity, and folding states of the displaying peptide.18, 19 An 
amplification efficiency of the individual M13 phage clone is determined by a 
combination of the above infection and secretion rates. To avoid negative effects on the 
infection/secretion, one should be aware of the following in an insert DNA construction. 
 
Signal peptidase cleavage. 
Positively charged basic amino acids, lysine and arginine, near the signal peptidase 
cleavage site inhibit the secretion of phages20 ; the cationic residue blocks translocation 
across the inner membrane of E. coli.21 If the N-terminus of the displaying peptide 
should be positively charged, lysine has to be evidently chosen; 6 out of 99 
arbitrarily-chosen clones of the commercial 12-mer library (Ph.D.-12) contained Lys at 
the terminus, whereas N-terminal Arg was never found in the same 99 clones.22 If the 
N-terminal Arg is inevitable, using non-commercial prlA suppressor strains such as 
ARI180 or ARI182 may help to avoid the secY-dependent secretion problem.20 
Pro at the terminus is also cumbersome. When proline is located next to the 
cleavage site, it inhibits the signal peptidase cleavage.23, 24 Only one N-terminal Pro out 
of the 99 clones was found in the Ph.D.-12 library.22 
If it is necessary to encode a specific amino acid sequence just after the signal 
peptidase cleavage site, prediction of the position-specific cleavage is recommended to 
avoid risks of inappropriate or insufficient cleavage. For example, an internet server, 
SignalP,25 instantly does this, and I usually use 0.3 for the threshold D-cutoff value in 
the gram-negative bacteria mode. 
(C) 2014 Keisuke Fukunaga, All Rights Reserved. 
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If one does not have any favorites of particular N-terminal sequence just after the 
cleavage site, “R-E” or simple “A” should be the first choice. There is an 
overabundance of negatively charged amino acids (E and D) at +1 and +2, and A at +1, 
in gram-negative signal peptidase cleavage sites (Fig. 3).22 
 
 
Figure 3. Sequence preference of the N-terminus of a peptide-pIII fusion (+1) in the M13 
system. X stands for any randomized amino acid.  
 
Unpaired Cys in a displaying peptide. 
If one generates a custom phage library displaying a disulfide-constrained peptide, 
an insert DNA encoding even number(s) of Cys, but not odd number(s) should be 
designed. This is because an intramolecular disulfide (S-S) bond could be formed 
between an unpaired Cys in a displaying peptide and an intrinsic Cys in the gp3.26 
Phage assembly, infection, and/or secretion could be prevented by this unfavorable 
disulfide bond.22, 27 It has been stated that an almost complete absence of odd number(s) 
of Cys was observed in the displaying peptide,26, 28 which is also identical to my 
experience. For example, when I sequenced 10 independent M13 phage clones 
encoding Cys-X7-Cys where the X stands for any randomized amino acid, no Cys was 
observed in the X7 region; only the designated Cys at both ends seemed to form an 
intramolecular disulfide bond. Given the difficulty, if one still tries to generate a phage 
(C) 2014 Keisuke Fukunaga, All Rights Reserved. 
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library containing odd number(s) of Cys, M13 phages constructed by disulfide-free 
gp329, 30 might be useful without using the Ph.D. system.  
(C) 2014 Keisuke Fukunaga, All Rights Reserved. 
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n 1.3 Characteristics of T7Select cloning system 
 
Unlike the filamentous M13 system, T7 capsid shell displaying peptide library is not 
involved in phage infection, and/or secretion. Indeed, it has been proven that libraries of 
the T7 phages exhibit less sequence bias than those of the M13 ones.27 This is a great 
advantage for library construction, because it is less necessary to pay attention to the 
amino acid sequences described above. The T7 system is also good at displaying a rigid 
motif with a hydrophobic domain, namely Trp cage.31 This peptide motif was never 
displayed on the M13 system, presumably because the hydrophobic domain was 
anchored to the inner membrane of the E. coli prior to the phage assembly.31  
 
Codon usage. 
To the best of my knowledge, there is no description of a relationship between 
codon usage and bias against translation for the T7 system in E. coli; in the M13KE 
system, it is reported that rare codons of E. coli seldom affect the bias of peptide 
libraries.22 To avoid potential risks that minor codons could stress the translation 
system,32, 33 I simply use major codons (Table 3) for a non-randomized region of a 
synthetic DNA insert. 
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Table 3. Codon usage in E. coli K-12 strain. 
Codon frequency, CF. CF is defined as the percent frequency of each codon which matches in 
whole open-reading frame of the E. coli K-12 genome. Minor codons (bold letters; < 0.5%) could 
be avoided for insert DNA construction. This table was cited from codon usage database 
(http://www.kazusa.or.jp/codon/) with some modifications. 
 
Unpaired Cys in a displaying peptide. 
In my experiment, when a T7Select415-1b vector was used for the T7 packaging, 
the T7 phage failed to display a designated unpaired Cys. In this case, the library insert 
DNA was constructed using the genetic code of (NNK)6-TGC-(NNK)6, which encodes 
X6-Cys-X6. DNA sequencing of 8 independent phage clones revealed that peptides were 
Amino 
acid 
Codon 
CF 
(%) 
Phe UUU 
UUC 
1.97 
1.50 
Ser UCU 
UCC 
UCA 
UCG 
0.57 
0.55 
0.78 
0.80 
Tyr UAU 
UAC 
1.68 
1.46 
Cys UGU 
UGC 
0.59 
0.80 
Leu UUA 
UUG 
CUU 
CUC 
CUA 
CUG 
1.52 
1.19 
1.19 
1.05 
0.53 
4.69 
Stop UAA 
UAG 
0.18 
0.00 
Stop UGA 0.10 
Trp UGG 1.07 
Pro CCU 
CCC 
CCA 
CCG 
0.84 
0.64 
0.66 
2.67 
His CAU 
CAC 
1.58 
1.31 
Arg CGU 
CGC 
CGA 
CGG 
AGA 
AGG 
2.11 
2.60 
0.43 
0.41 
0.14 
0.16 
Gln CAA 
CAG 
1.21 
2.77 
Ile AUU 
AUC 
AUA 
3.05 
1.82 
0.37 
Thr ACU 
ACC 
ACA 
ACG 
0.80 
2.28 
0.64 
1.15 
Asn AAU 
AAC 
2.19 
2.44 
Lys AAA 
AAG 
3.32 
1.21 
Ser AGU 
AGC 
0.72 
1.66 Met AUG 2.48 
Val GUU 
GUC 
GUA 
GUG 
1.68 
1.17 
1.15 
2.64 
Ala GCU 
GCC 
GCA 
GCG 
1.07 
3.16 
2.11 
3.85 
Asp GAU 
GAC 
3.79 
2.05 
Gly GGU 
GGC 
GGA 
GGG 
2.13 
3.34 
0.92 
0.86 
Glu GAA 
GAG 
4.37 
1.84 
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truncated by the appearance of a TAG stop codon before the designated Cys that was 
supposed to be translated (Fig. 4A). 
The capsid shell used for randomized peptide display is composed of 415 copies of 
gp10.34 A structural study of T7 procapsid shell suggested that the gp10 might play an 
important role in the interaction between capsid shell and scaffolding proteins.35 The 
designated Cys in the library peptide fused to the gp10 might form an intermolecular 
disulfide bond with the same kind of unpaired Cys in a neighboring library peptide. It 
also might form an intramolecular one with an intrinsic Cys in the gp10. Too many 
unpaired Cys may inhibit proper/efficient assembly of the capsid shell proteins. 
Although I do not have direct evidence for this hypothesis, Rosenberg et al. also 
speculated that some peptide sequences might be unfavorable for the T7Select415 
system.16 
 
 
Figure 4. Unexpectedly isolated highly biased clones after library constructions. Underlined X 
indicate any amino acids. (A) Stop codon appearance before the designated Cys in the T7 
system. A combination of T7Select415 vector and E. coli BL21 strain was used for in vitro 
packaging, and individual clones were subjected to DNA sequencing. For the sequence 
(C) 2014 Keisuke Fukunaga, All Rights Reserved. 
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alignment, ESPript program (http://espript.ibcp.fr/) was used. (B) Enrichment of a biased 
sequence and a mutation of the designated His. Asterisk indicates the mutated region. 
Randomly selected 12 individual M13 clones were subjected to DNA sequencing. Parentheses 
indicate numbers of the obtained clones. 
 
Paired Cys in a displaying peptide. 
Phages displaying the cyclic peptide by an intramolecular disulfide bond tend to 
exhibit higher target-binding ability, because their rigid structures minimize 
conformational entropy loss associated with the binding.36, 37 Therefore, this kind of 
phage library is dominantly used for screening on the basis of not only M13 systems 
(e.g., Ph.D. -C7C library from NEB) 36, 38 but also T7 ones.39, 40 Disulfide constrained 
library of the T7 phage is most frequently constructed by using T7Select10-3b27, 41 or 
415-1b vector42-45 (Table 2).	   
For generation of the disulfide constrained (S-S) library using the T7Select415 
system, it is recommended in the manual (Merck Millipore) to use E. coli Origami B or 
Rosetta-gami B strains, which tends to enhance disulfide bond formation in the 
cytoplasm. However, these strains may not be required for the library constructions. By 
using E. coli BLT5615 strain included in the T7 kit with the T7Select10-3b27 or 
415-1b45 vectors, the constrained library peptides were successfully displayed on the T7 
phage, and high-affinity cyclic peptides were obtained.  
 
Features of the T7 system. 
One of the features of the T7 phage, which grows much faster than the M13 one, is 
that it decreases the time for phage titering and amplification. After infection, clear 
plaques of T7 phages will usually appear within 2-3 hours on LB plate with no additives. 
Liquid amplification of the T7 phage after affinity selection can also be conducted 
within the same time.  
It is also attractive for beginners that the T7 system does not require any special 
instruments like an electroporator for the library construction. Contrary to the kit 
instructions, ultracentrifugation of the T7 phage with CsCl is not necessary for all 
(C) 2014 Keisuke Fukunaga, All Rights Reserved. 
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purification processes of ELISA assay and DNA sequencing. General procedure using 
polyethylene glycol (PEG)/NaCl with a conventional rotator is enough for the T7 phage 
purification, in the same way as the M13 system. 
The T7 system can be useful for direct recovery of the highest affinity phage with a 
very slow off-rate from a target-linked solid support. It has been reported that a 
target-bound lambda phage can be directly amplified by the addition of E. coli in 
mid-log phase.46 In a similar way, a library peptide displayed on the capsid shell does 
not interfere with the infectivity of the T7 phage. Indeed, I have experienced that a 
streptavidin-binding peptide containing the consensus sequence (H-P-Q)47 was 
successfully obtained by this direct method (data not shown). In the M13 system, 
phages may also be eluted by the addition of the host bacterial cells, however the 
elution of the highest affinity binders may be hindered. 
A minor drawback of the T7 system is that it is relatively expensive to construct a 
library with a high diversity. In a typical case, six whole tubes of T7 packaging extracts 
in a T7Select packaging kit (ca., $410) are required to obtain a diversity of 4.1 × 108 
PFU.45 
 
Handling precautions. 
It should be emphasized that in vitro packaging has to be performed with extreme 
care. One must keep a stringent condition of the temperature and mixing. Only “fresh” 
T7 packaging extract will make a high quality library; freezing and thawing of the 
extract will result in apparent reduction of the packaging efficiency. 
Diluted T7 phages with a buffer or water tend not to be infective. It should be 
diluted with a buffer containing a protectant such as gelatin, or a growth media such as 
TB or LB. 
(C) 2014 Keisuke Fukunaga, All Rights Reserved. 
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n 1.4 Importance of DNA sequencing for finding unfavorable bias 
and false-positives at an early stage of the affinity selection  
 
After the electroporation for the Ph.D. system or the packaging for the T7Select 
system, a qualitative assessment of the phage library should be performed by DNA 
sequencing prior to the biopanning. I always confirm it by a conventional DNA 
sequencer with at least 10 independent phage clones. For example, I obtained highly 
biased sequences when the random library encodes constraints with a His6-tag 
(A-C-X4-H6-X4-C) (Fig. 4B). In this case, a specific sequence was predominantly 
enriched (C-F-S-R-S-H-H-H-H-H-H-H-L-L-Y-C; 7 out of 12 arbitrarily-chosen clones). 
In addition, one of the designated His at the 3rd position of the His6-tag was mutated to 
Arg accompanied with a codon replacement from CAC to CAT. Nature seems to 
exclude the constrained His-tag in the M13 system, and such a library should not be 
used for the biopanning. 
 
Advantage of high-throughput DNA sequencing. 
A next generation sequencer (NGS) makes it possible to sequence millions of inserts 
in parallel. If the NGS is available, one million reads of the library clones would be 
ideal for finding target-binding sequences even after first round of the biopanning (Fig. 
5).48 If false positive sequences such as target-unrelated (e.g., plastic or BSA) binders or 
propagation accelerating peptide (e.g., H-A-I-Y-P-R-H)49 are predominantly enriched at 
an early stage, further biopanning will be useless. These meaningless false-positive 
sequences are well-described and summarized in a recent-published review,50 and can 
be found easily with online databases (SAROTUP51, http://immunet.cn/sarotup/; 
PepBank52, http://pepbank.mgh.harvard.edu/). Once candidate clones are selected after 
several rounds of biopanning, the false positive sequences should be excluded in the 
same manner. If the DNA sequencing is performed by a conventional sequencer but not 
by the NGS, one should be aware that the DNA sequencing of 50 randomly-chosen 
clones after first or second rounds of the biopanning would be completely 
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uninformative for finding target binders, because the population will be lacking48; it 
should be performed at a later round. 
 
 
Figure 5. Phage display screening with next generation sequencing. (A) Biopanning with one or 
two-cycle(s). (B) Randomized-region of phage DNA is amplified with Polymerase Chain 
Reaction (PCR). The products are subjected to gel electrophoresis followed by further DNA 
purification. (C) Purified DNA is analyzed by a next generation sequencer. 
(C) 2014 Keisuke Fukunaga, All Rights Reserved. 
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n 1.5 Conclusions 
Merits and demerits of the M13 and T7 systems are summarized in Table 4. It seems 
that the T7 system is easier to handle for beginners, because there are several 
engineering tolerances. Additionally, the T7 phage is stable to detergents and 
denaturants (e.g., 1% sodium dodecyl sulfate (SDS), urea (up to 4 M), and 
guanidine-HCl (up to 2 M)), for eliminating non-specific binders during the biopanning. 
Although the T7 phage is robust against not only the chemicals but also an alkaline 
condition (pH 10), it is fragile at acidic conditions below pH 4. If an elution from 
target-linked solid support under the lower pH is necessary, the M13 system should be 
the first choice. 
In both systems, the DNA sequencing of a constructed phage library before 
biopanning is highly recommended for finding unexpected bias. 
 
Table 4. Comparison of the M13 and T7 phage in library construction and affinity selection. 
 M13 phage T7 Phage 
Cost 
routinely cheap, 
requires electroporator 
and cuvettes 
routinely expensive, no 
additional instruments 
required 
Site of library peptide N-terminus of gp3 C-terminus of gp10B 
Library size / mg DNA ~109 ~108	 45 
Peptide sequence bias  highly biased less biased 
Time required for phage 
titering/amplification 
long short 
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CHAPTER 2 
 
Construction of a 
tetramethylrhodamine-conjugated 
peptide library and selection of 
glutathione S-transferase-binders 
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n Abstract 
 
Phage display technology is a powerful tool to construct peptide library and to 
screen a target-specific binder. However, the displayed peptide cannot always have an 
optimal structure to interact with a target of interest. Post-translational chemical 
modification is an approach to get over this problem. By using the method, one peptide 
library can be perfectly converted to another library, which may contain the optimal 
molecule for the interaction. In this chapter, site-specific conjugation with a 
haloacetamide derivative into a designated cysteine on a displaying peptide on a capsid 
protein (gp10) of bacteriophage T7 has been achieved. This easiest gp10-based 
thioetherification (10BASEd-T) is carried out in one-pot without side reactions or loss 
of phage infectivity. Here, tetramethylrhodamine-conjugated library is constructed, and 
glutathione S-transferase-specific binders are obtained from the library. 
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n 2.1 Introduction 
 
Recently, construction of a peptide library containing non-natural structures has 
been attracting much attention for drug discovery. Most frequently, non-natural amino 
acids as artificial structures are incorporated into specific position(s) of the peptide by 
an in vitro translation system along with genetic code reprogramming.1-4 This 
sophisticated system has a great advantage in terms of peptide diversity. However, 
usage of an expensive cell-free translation system as well as fragile RNAs is required 
for the library construction. Another problem is that not all non-natural amino acids can 
be incorporated because E. coli ribosome excludes certain structures of the amino acids 
such as large aromatic ones.6 
Post-translational chemical modification of a phage-displayed peptide is an 
alternative approach for the construction of a non-natural peptide library.7, 8 Although 
the diversity of the phage library is smaller than the in vitro translated one, the phage 
display technology10 is more accessible in terms of cost and handling. A pioneering 
work of the non-natural peptide library construction on the phage is reported by 
Winter’s group in 2004. They successfully developed a fluorogenic biosensor by 
conjugating a fluorophore with a designated Cys at the antigen-binding site of a 
phage-displayed antibody library.11 To date, Heinis has preceded this field with 
chemically constrained bicyclic peptides on the phage.12-14 In such cutting-edge studies, 
M13 phage has been exclusively used until today. However, the library contains an 
inherent bias of amino acid sequences because secretion of M13 phage from E. coli 
closely depends on charges, hydrophilicity, and folding states of the M13-displayed 
peptides.15-17 Moreover, it is reported that the side reaction against the intrinsic Cys of 
the minor coat protein (gp3) occurred in the post-translational chemical modification.12
 
In my independent study, not only gp3 but also various M13 phage proteins were 
modified (Fig. 1), suggesting that site-specific modification of the M13-displayed 
peptide was extremely difficult. To avoid the side reaction, genetically engineered M13 
phage carrying Cys-free gp3 is often used.12-14, 18 Even though the site-specific chemical 
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modification of the M13-displayed peptides is achieved, it results in a significant 
decrease of the infectivity titer.12 
The T7 system is also used for the phage display,19 and is superior to the M13 one 
in view of the sequence bias and growth rate.17, 20 A recent structural study of the T7 
major capsid protein (gp10) reveals that two intrinsic Cys of the gp10 are buried inside 
of the mature capsid (Fig. 2).21
 
On the other hand, the library peptide fused to the 
C-terminus of the gp10 has to be located outside of the capsid to come in contact with 
various targets. These facts motivated us to carry out straightforward chemical 
modification of the T7 phage-displayed peptide without construction of Cys-free gp10; 
because of steric hindrance, the intrinsic Cys will not be modified. Here the introduction 
of non-natural groups into a designated Cys on the T7-displayed peptide, namely gp10 
based-thioetherification (10BASEd-T), was performed as shown in Schemes 1 and 2. 
 
 
Figure 1. Chemical modification against M13-displayed peptide library. 5-TMRIA was used for 
the modification. Experimental condition was the same as 10BASEd-T. Ph.D. -C7C phage 
display peptide library was purchased from New England Biolabs (cat. No. E8120S). 
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Figure 2. A structural model of hexametric gp10 (RCSB Protein Data Bank ID: 2XVR) revealed 
that the intrinsic thiol groups of the gp10 (Cys146 and Cys209) are buried inside of the mature 
capsid.1 The structures were generated by RasMol software (http://rasmol.org/). 
 
 
Scheme 1.  Site-specific introduction of a non-natural group (R) into the designated Cys on a 
T7 phage-displayed peptide by the 10BASEd-T. 
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Scheme 2.  Thioetherification of SH-group on peptide by SN2 reaction. 
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n 2.2 Results and discussion 
 
Tetramethylrhodamine-5-iodoacetamide (5-TMRIA) was used as a model alkylating 
reagent, because it can be easily analyzed by fluorescence imaging, liquid 
chromatography (LC), and fluorescence polarization (FP) assay. For the site-specific 
introduction of tetramethylrhodamine (TMR) via the 10BASEd-T, I only mixed 
5-TMRIA (200 µM) with the T7-displayed peptide (1.0 × 1011 plaque forming units of 
the T7 phage) in 700 µL of phosphate-buffered saline (pH 7.4) supplemented with 500 
µM tris(2-carboxyethyl)phosphine (TCEP) and 400 mM NaCl at 4°C. After 3 hours of 
reaction, whole T7 phage proteins were subjected to sodium dodecyl sulfate 
poly-acrylamide gel electrophoresis (SDS-PAGE), followed by fluorescence imaging. A 
single fluorescent band could be seen at an appropriate molecular weight (ca., 44 kDa) 
of the peptide-fused gp10 (Fig. 3A; upper panel, lane 3). This indicates that the 
alkylation exclusively occurred at the peptide-fused gp10. Note that neither protein 
components required for the infection nor other T7 phage molecules were reacted. 
Several reports stated that trialkylphosphines unfavorably react with haloacetic acids 
and their amide derivatives.22, 23 Thus, the reduction and alkylation are usually 
performed in two separate steps.11, 12, 24 Contrary to popular belief, chemical 
modification of the peptides with TCEP and 5-TMRIA could be performed in one-pot 
without tedious purification of the reduced intermediate. For site-specific modification 
of the T7-displayed peptides, the optimal molar concentration of 5-TMRIA was around 
200 µM; higher concentration gave non-specific modification (Fig. 4). To quantitate the 
efficiency of the 10BASEd-T, Western blot analysis was performed by using a FLAG 
epitope, which is located between gp10 and the T7-displayed peptide. After the 
modification, the original band of the FLAG-tagged protein almost disappeared. Instead, 
a band of a slightly higher molecular weight appeared (Fig. 3A; lower panel, lanes 1 
and 3). In the Western blotting-based quantification, it was estimated that at least 95% 
of the peptide-fused gp10 had been modified (data not shown). Next, I examined 
whether TMR was conjugated only to the T7-displayed peptides but not to the intrinsic 
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Cys of gp10. To confirm this, the modified peptide-fused gp10 was site-specifically 
cleaved at the end of the FLAG-tag by enterokinase. As expected, the fluorescence band 
totally disappeared after enterokinase digestion (Fig. 3A; upper panel, lanes 3 and 4), 
suggesting that TMR was appropriately conjugated only to the T7-displayed peptide. 
 
To achieve more precise characterization, I performed a mass spectrometric analysis 
of the fluorophore-conjugated peptide. MS analysis of the phage-displayed peptide is 
challenging because a small amount of peptides is obtained in a batch.8 In the case of 
the T7 phage, only ca. 10 molecules of the peptides are displayed per single virion, 
when a mid-copy phage display vector (T7Select10) is used.25
 
To bypass this problem, I 
generated a model T7 phage carrying approximately 200 molecules of the peptides per 
single virion26
 
by using a high-copy vector (T7Select415). After the 10BASEd-T 
followed by SDS-PAGE, the fluorescent band in the gel was excised (Fig. 3B) and 
digested with trypsin. The resulting peptide fragments were analyzed by LC-MS/MS. 
Two chromatographic peaks at 550 nm (TMR absorption) were detected (Fig. 3C; upper 
panel), and each of them was identified as the TMR-conjugated T7-displayed peptide 
by tandem mass spectrometry (Fig. 3C; lower panel). Also these data suggest that the 
two TMR molecules were conjugated to the two designated Cys on a single 
T7-displayed peptide. The TMR-conjugation was also validated by LC-MS analysis of 
the lysyl endopeptidase-digested sample (Fig. 5). At the same time, most of the other 
peptide fragments derived from gp10 were identified by peptide mass fingerprinting 
based on MS/MS ion search (data not shown). 
 
Next, I performed the 10BASEd-T on a T7 phage library generated from the 
mid-copy vector. In-gel fluorescence imaging and Western blot analysis should that 
almost all of the peptide-fused gp10 were modified (Fig. 3D). On the other hand, a 
small amount of the peptide-fused gp10 remained at the same original position (Fig. 3D; 
lower panel). These faint bands were considered to be truncated peptide-fused gp10 
without Cys as shown in Fig. 6 (lanes 2 and 6). These data indicate that the 
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T7-displayed peptides can be modified in a sequence independent manner only if Cys is 
present in the peptide. 
 
 
Figure 3. (A) Fluorescence imaging of TMR-modified T7 phage proteins, and site-specific 
cleavage of peptide-fused gp10 by enterokinase. Here, a model T7 phage carrying a mid-copy 
vector was modified via the 10BASEd-T. Western blotting against FLAG-tag (lower panel) was 
performed with the gel shown in above panel. Triangles, squares, and circles represent 
TMR-conjugated peptide-fused gp10, intact one, and enterokinase-digested one, respectively. 
(B) Introduction of TMR onto T7-displayed peptide via the 10BASEd-T. Here, a model T7 phage 
carrying a high-copy vector was used. The dashed square corresponding to TMR-conjugated 
peptide-fused gp10 was excised and subjected to in-gel trypsinization followed by LC-MS/MS 
analysis. CBB indicates coomassie brilliant blue staining. (C) Identification of peptide fragments 
derived from the TMR-conjugated T7-displayed peptide by LC-MS/MS. Upper panel: 550 nm 
(TMR absorption) chromatogram of the trypsinized peptide-fused gp10. Middle and lower panel: 
MS/MS spectrum corresponding to each of the two chromatographic peaks. Note that trypsin 
(C) 2014 Keisuke Fukunaga, All Rights Reserved. 
 31  
could not cleavage before proline.9 (D) TMR-modification of T7-displayed library peptides via the 
10BASEd-T. 
 
 
Figure 4. Optimization of 5-TMRIA concentrations. The T7 phage clones were modified via the 
10BASEd-T with various molar concentrations of 5-TMRIA under the standard condition 
(described in Materials and Methods). Equal amounts of phage proteins were subjected to 
SDS-PAGE followed by fluorescence imaging. 
 
 
Figure 5. LC-MS analysis of lysyl endopeptidase-digested gp10 fusion. Upper panel: HPLC 
chromatogram of the digested gp10. The 550 nm absorption corresponding TMR absorption was 
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monitored. Lower panel: MS spectrum of the corresponding peak at 24.26 min. A series of 
multiple charged ions were detected (experimental m/z values 1295.1, 864.0, 648.5, 519.0, and 
432.7), and consistent with theoretical m/z values of the TMR-conjugated peptide (calculated 
m/z values 1295.6, 864.1, 648.3, 518.8, and 432.5). Lys-C represents lysyl endopeptidase. 
 
 
Figure 6. Introduction of tetramethylrhodamine (TMR) into different peptide-fused gp10. Amino 
acid sequences of the peptides are shown in right panel. A triangle and an asterisk (*) represent 
the TMR-conjugated gp10 and contaminated protein derived from E. coli, respectively. Two 
clones lacking Cys in T7 phage-displayed peptide were not modified (clones 2 and 6). In case of 
these clones, T7-displayed peptides were truncated by the appearance of a stop codon before 
the designated Cys that was supposed to be translated. 
 
 
When using a phage-displayed peptide library along with the post-translational 
chemical modifications, one concern is the negative effect on infectivity for E. coli.8 
Therefore, I examined the infectivity of the TMR-conjugated T7 phage peptide library 
by plaque assay. As shown in Fig. 7, the modified T7 phage completely retained its 
infectivity. A similar observation has been recently reported; an enzyme treated-T7 
phage fully retains the infectivity, whereas the treated-M13 phage does not. These data 
suggest that the T7 phage is an excellent platform for post-translational modifications. 
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Figure 7. Infectivity of modified T7 phage. A T7 phage library was treated with or without 
5-TMRIA in the presence of TCEP under the standard condition (described in Experimental 
selection). The number of plaque forming units was determined by serial dilution method and 
plaque assay. The graph summarizes the results of three independent experiments. Error bars 
represent standard deviations. Statistical analysis was performed by unpaired Student’s t-test. 
n.s., not significant (p values = 0.17 [left] and 0.31 [right], respectively). 
 
I next attempted to find target-protein specific binders from TMR-conjugated 
peptide libraries (Fig. 8). As a model target protein, I chose glutathione S-transferase 
(GST) because it is thought to be a potential therapeutic target for cancer.28, 29 Prior to 
biopanning, mixed T7 libraries carrying X3-C-X5–7-C-X3 peptides (where X represents 
any amino acid) were modified through the 10BASEd-T. To include the possibility that 
a doubly-alkylated peptide may improve the affinity toward the target protein, I 
conjugated two TMRs into each library peptide with two Cys. Five rounds of 
biopanning were performed against biotinlylated-GST, and enrichment of the 
GST-binders was confirmed by enzyme-linked immunosorbent assay (ELISA). To 
examine whether the amide or the TMR moiety is required for the binding, 
5-TMRIA-treated T7 phage polyclones and iodoacetamide (IA)-treated ones were 
subjected to ELISA in parallel. After 5 rounds, the TMR-conjugated T7 phage 
polyclones should the strongest binding to GST (Fig. 9A). This indicates that the TMR 
moiety of the peptides plays a crucial role in interaction with GST. I found that all 5 
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clones randomly chosen from the phage pool after 5 rounds had a consensus sequence 
of C*-X-X-D-G-Y/F (C* and X represent alkylated Cys and any amino acid, 
respectively) (Fig. 9B). Among them, 3 clones bound only to GST when it was 
modified with 5-TMRIA but not IA (Fig. 9B and 10; clones 1, 4, and 5). Thus, I 
chemically synthesized one of them, TMR-conjugated Ac-R-M-W-C*-T-H-D-G-Y-OH 
peptide (equivalent to clone 5 shown in Fig. 9B and 10), and examined its binding 
affinity to GST by FP assay. GST-specific binding of the TMR-conjugated peptide was 
observed (Fig. 9C), whereas negative control peptides did not bind to GST (Fig. 11). 
The dissociation constant (KD) of the TMR-conjugated peptide was estimated to be 3.6 
µM (Fig. 9C). 
Glutathione (GSH) is a well-known GST-binding tripeptide. I next examined 
whether the TMR-conjugated peptide inhibits GSH-GST interaction. But there are two 
possible interfere mechanisms: one is competitive binding. Another is structure change 
of the TMR-conjugated peptide and/or GST under reducing condition, because GSH 
could behave as a reducing agent. To exclude the possibility that reducing condition 
interfere with association of the TMR-conjugated peptide with GST, TCEP was used as 
mock competitor. By addition of GSH but not TCEP, the interaction was abolished (Fig. 
12A), indicating that the TMR-conjugated peptide would be a GSH competitor. This 
was confirmed by competitive elution of GST from GSH-coupled beads (Fig. 12A). 
However, I cannot exclude the possibility of allosteric inhibition. 
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Figure 8. Schematic diagram of biopanning used in this study. (A) Construction of 
TMR-conjugated peptide library on T7 phage through the 10BASEd-T. (B) Incubation of the 
phage display peptide library with immobilized glutathione S-transferase (GST). (C) Washing of 
unbound phage. (D) Amplification of the GST-bound phage for subsequent rounds of the 
biopanning. 
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Figure 9.  (A) ELISA of modified T7-displayed peptides against biotinlylated-GST or bovine 
serum albumin (BSA). T7 phage polyclones after each round of biopanning were modified with 
iodoacetamide (IA) or 5-TMRIA, and then subjected to ELISA. BSA was used as a negative 
control to examine non-specific binding. (B) Sequence alignment of GST-binding peptides of 
randomly chosen T7 clones from phage pool after 5 rounds of biopanning. Consensus 
sequences are highlighted. For the alignment, ESPript program5 was used. ELISA signal 
intensities are shown in right. (C) Determination of GST-binding affinity of the TMR-conjugated 
Ac-R-M-W-C-T-H-D-G-Y-OH peptide by FP assay. The circles and squares indicate the 
polarizations (mP) of the peptide in the presence of various concentrations of GST or BSA, 
respectively. 
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Figure 10.  ELISA analysis by using T7 phage clones that randomly chosen from phage pool 
after 5th biopanning. Peptide sequences displayed on the phage are shown in right panel 
(clones 1 to 5). The graph summarizes the results of three independent experiments. Error bars 
represent standard deviations. IA and BSA represent iodoacetamide and bovine serum albumin, 
respectively.  
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Figure 11.  Fluorescence polarization assay by using negative control peptides. (A) 
Competitive binding assay. Unmodified peptides were mixed with TMR-conjugated peptide-GST 
complex in the presence of dithiothreitol (2 mM) in phosphate-buffered saline. The molar ratio of 
the competitor to TMR-conjugated peptide is represented in the upper part. (B) Binding of 
nitrobenzofurazan (NBD)-conjugated peptide with GST or BSA. When the TMR moiety was 
substituted to NBD moiety, the GST-specific binding of the peptide was drastically prevented. (C) 
Binding of TMR-conjugated unrelated peptide. The GST specific binding of the TMR-conjugate 
never occurred because the peptide sequence was totally different from that of the GST-binding 
peptide. 
 
 
Figure 12.  (A) Competitive binding assay. GSH was mixed with TMR-conjugated peptide-GST 
complex in phosphate-buffered saline. TCEP served as a mock competitor. The molar ratio of 
GSH to TMR-conjugated peptide is represented in the upper part. (B) Competitive elution of 
glutathione S-transferase (GST) from GSH-coupled sepharose. 
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In conclusion, I established a general and instant method of post-translational 
chemical modification for the T7 phage-displayed peptide library. The reactivity and 
specificity of the 10BASEd-T on the T7 phage were as excellent as those of enzymatic 
introduction of functional groups on proteins.30 To my knowledge, this is the first 
demonstration of a construction of a T7-displayed peptide library containing 
non-natural structures. Numerous alkylating reagents (e.g., haloacetamide derivatives) 
are commercially available, and such compounds can be synthesized in a simplest 
way.31
 
I envision that the 10BASEd-T will be a standard method for construction of 
peptide-based hybrid libraries. 
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n 2.3 Experimental procedures 
 
General 
All experiments were performed with commercially available reagents and kits. 
Note that no special materials and skills are needed. Contrary to popular belief and 
T7Select system manual (Merck Millipore), CsCl step gradient and ultracentrifugation 
are not necessary to perform all of the experiments to obtain target-specific binder.2 For 
purification of T7 phage at every step by polyethyleneglycol / NaCl precipitation, I only 
used conventional centrifugation system which can rotate at 13,000 rpm. 
 
Construction of T7 phage display library 
FLAG-tagged T7 phage peptide library (-S-G-G-G-G-FLAG-G-S-X3-C-X7-C-X3; 
where X represents any randomized amino acid) was constructed with T7Select10-3b 
(used in Figures 1A and 1D) or T7Select415-1b (used in Figure 1B) system according 
to the kit instructions (Merck Millipore). In brief, an oligonucleotide was synthesized in 
the following format: 5’- 
GGTGGAGGTGGCGACTACAAGGATGACGATGACAAGGGATCA 
(NNK)3TGC(NNK)7TGT(NNK)3TGAAAGCTTGGA-3’. The oligonucleotide was 
amplified by polymerase chain reaction (PCR) using an appropriate set of primers 
harboring restriction sites for EcoRI and HindIII, respectively. The PCR products were 
purified, and then digested with EcoRI and HindIII. The DNA fragments were further 
purified and ligated to the vectors. The ligation products were subjected to in vitro 
packaging with T7 packaging extracts followed by infection into Escherichia coli 
BLT5403 cells. Noted that an amplification of T7 phage carrying a T7Select415-1b 
vector by using BLT5403 cells causes medium-high-copied peptide display (200 
peptides per virion).26 One of the T7 phage display peptide library 
(-S-G-G-G-X3-C-X7-C-X3) was constructed in a previous study.32 Another T7 phage 
display peptide library (-S-G-G-G-X3-C-X5-6-C-X3) was constructed in the same 
manner. Quality and complexity of the phage display peptide libraries were checked by 
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DNA sequence analysis of PCR-amplified DNA fragments from randomly chosen 
phage clones. For DNA amplification, following oligonucleotides were used: 
5’-CGCTAAGTACGCAATGGGCC-3’ (forward primer), 
5’-GTCTCAACGTTCATATCGTATGAGCG-3’ (reverse primer).  
 
Chemical modification of T7 phage via the 10BASEd-T  
Standard reaction condition of the 10BASEd-T is the following. The reaction was 
carried out in 1.5 mL microcentrifuge tubes. T7 phage particles (approximately 1.0 × 
1011 PFU) were dissolved in a 700 µL of phosphate-buffered saline (Nacalai, cat No. 
14249-95) supplemented with 400 mM NaCl, and well suspended by sonication (vortex 
is also available). At this moment, the buffer was containing 1.0 × 1012 (T7 phage made 
by T7Select10-3b system) or 2.0 × 1013 (by T7Select415-1b system) molecules of the 
T7-displyed peptides. After centrifugation at 12,000 rpm for 5 minutes at room 
temperature, the supernatant was mixed with neutralized tris(2-carboxyethyl)phosphine 
(TCEP-NaOH; final concentration of 500 µM) at 4 °C. At this time, the TCEP stock 
aqueous solution of pH 7 was prepared by neutralization with NaOHaq in advance. 
Tetramethylrhodamine-5-iodoacetamide (5-TMRIA; Molecular Probes, cat. No. 
T-6006) was added at a final concentration of 200 µM, and the mixture was incubated at 
4 °C for 3 hours in the dark with shaking. 5-TMRIA was dissolved in dimethyl 
sulfoxide/water (1:1 by volume) in advance. To inactivate the unreacted 5-TMRIA, 
2-mercaptoethanol was added to the mixture at a final concentration of 5 mM, and 
further incubated at 0 °C for several minutes. The T7 phage particles were precipitated 
with a mixture of polyethylene glycol 6000 and sodium chloride to final concentrations 
of 5% (w/v) and 0.5 M, respectively. After centrifugation, the precipitate was dissolved 
in an appreciate buffer. 
 
In-gel fluorescence imaging and Western blot analysis 
T7 phage particles were dissolved in 1 × sample buffer (62.5 mM 
tris(hydroxymethyl)aminomethane-HCl, pH 6.8, 10% glycerol, 2% SDS, 5% 
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2-mercaptoethanol, 0.002% bromophenol blue). The solution was incubated at 95 °C for 
5 min, and then subjected to SDS-PAGE. Proteins were resolved by a 10% or a 10-20% 
gradient SDS–polyacrylamide gel. After electrophoresis, the TMR-conjugated proteins 
were visualized by in-gel fluorescence imaging using a fluoroimager (FMBIO III-SC01, 
Hitachi, Japan) as reported previously.33 A band-pass filter (555 BP20) was used for the 
detection. A conventional gel imager excited by UV light, such as Gel Doc XRS+ 
(Bio-Rad), can also take the image. 
Western blot analysis was performed as described previously.34 In brief, proteins in 
the gel were transferred onto a polyvinylidene difuoride (PVDF) membrane (Bio-Rad), 
and then the membrane was subjected to blocking with bovine serum albumin. The 
blots were incubated with anti-FLAG M2 mouse monoclonal antibody (1/1,000 
dilution; Sigma Aldrich), followed by incubation with anti-mouse IgG horseradish 
peroxidase-conjugated secondary antibody (1/5,000 dilution Cell Signaling 
Technology). After several washes, the blots were incubated with ECL plus reagent (GE 
Healthcare Life Sciences), and detected using a ChemiDoc XRS+. Image contrast and 
brightness were adjusted in Photoshop CS4 (Adobe). 
 
Site-specific cleavage of T7-displayed peptides by enterokinase  
Site-specific cleavage of peptide-fused gp10 was performed as previously 
described.31 In brief, non-denatured T7 phage particles were suspended in a reaction 
buffer (20 mM tris(hydroxymethyl)aminomethane-HCl, pH 7.4, 50 mM NaCl, 2 mM 
CaCl2) in the presence or absence of 0.1 units of recombinant enterokinase (Merck 
Millipore), and incubated at 37 °C for 16 hours. The reaction was stopped by an 
addition of 4 × sample buffer. 
 
Mass spectrometric analysis 
For mass spectrometric analysis, a PAGE gel was stained with a rapid stain CBB kit 
(Nacalai, Japan). The stained protein bands were excised from the gel. Proteins in the 
gel were reduced with 25 mM dithiothreitol at 65 °C for 10 min, and then alkylated with 
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55 mM iodoacetamide at room temperature for 60 min in the dark. Digestion was 
carried out with modified trypsin (Promega, Madison, WI) or lysyl endopeptidase 
(Wako, Japan) at 37 °C overnight. The resulting peptides were analyzed using an 
Agilent 1100 HPLC system (Agilent Technologies) equipped with a C18 reverse-phase 
column (Hypersil GOLD, 2.1 × 100 mm, Thermo Fisher Scientific) connected to a 
LCQ-Fleet mass spectrometer. The peptides were separated using a 0-50% gradient of 
acetonitrile containing 0.1% formic acid during 40 min at a flow rate of 300 µL per a 
minute, and then eluted peptides were directly sprayed into the mass spectrometer. The 
mass spectrometer was operated in the data-dependent mode and externally calibrated. 
Survey MS scans were acquired in the 400-2000 m/z range. Multiply charged ions of 
high intensity per scan were fragmented with CID in the ion trap. A dynamic exclusion 
window was applied within 30 seconds. All tandem mass spectra were collected using 
normalized collision energy of 35%. Data were acquired and analyzed with Xcalibur 
software (Thermo Fisher). 
 
GST expression and biotinylation followed by biopanning 
For preparation of GST protein, pGEX-4T-3 vector (GE Healthcare) was introduced 
into E. coli BL21 (DE3) strain. Transformants were precultured overnight at 37°C in 10 
mL of LB medium supplemented with 100 µg/mL ampicillin, and then transferred to a 
200 mL of fresh medium. After incubation for 2 hours at 37 °C, isopropyl 
β-D-1-thiogalactopyranoside was added at a final concentration of 0.2 mM, and the 
cells were further cultured for 2 hours. The cells were harvested, and suspended in 
B-PER protein extraction reagents (Thermo Scientific) supplemented with lysozyme. 
After incubation for 1 hour at 4 °C, the sample was cleared by centrifugation at 20,000 
× g (13,000 rpm) for 10 min at 4 °C. Supernatant was incubated with glutathione 
sepharose 4B (GE Healthcare). After several washing with tris-buffered saline 
supplemented with 0.5 % Triton X-100, GST protein was eluted with glutathione 
elution buffer (50 mM PIPES-KOH, pH 7.4, 100 mM NaCl, 1 mM dithiothreitol, and 
50 mM reduced glutathione). The eluted protein was desalted by ultrafiltration, and then 
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subjected to biotinylation with a biotin labeling kit (DOJINDO, Japan) followed by 
purification. The biotinylation of the GST was confirmed by Western blotting. Purity of 
the biotinlylated-GST was estimated to be above 95%. 20 pmol of the 
biotinlylated-GST was immobilized on streptavidin-coupled Dynabeads (Invitrogen). 
 For biopanning, approximately 8.4 × 1010 PFU of T7 phage display peptide libraries 
(-S-G-G-G-X3-C-X5-7-C-X3; X represents any randomized amino acid) were modified 
via the 10BASEd-T. To eliminate T7 phage that bound to the Dynabeads, the modified 
T7 phage display peptide library was dissolved in selection buffer (phosphate-buffered 
saline supplemented with 1% Triton X-100 and 1% bovine serum albumin), and 
pre-incubated with the beads for 2 hours at 4 °C. Then, the supernatant was further 
incubated with the biotinylated-GST immobilized Dynabeads for 2 hours at 4 °C. The 
beads were washed three times with 200 µL of the selection buffer, and the GST-bound 
phage was directly infected and amplified with E. coli BLT5403 cells. Stringent 
conditions were stepwisely applied to each round by shortening the binding time and by 
increasing the washing frequency. After 5th rounds of the panning, randomly chosen T7 
phage clones were subjected to DNA sequencing. Overview of the biopanning in this 
study was shown in Figure 8. 
 
Enzyme-linked immunosorbent assay (ELISA) 
830 pmol of streptavidin (Promega) was dissolved in phosphate-buffered saline 
(PBS), and immobilized on each well of a 96 well immunoplate (Nunc MaxiSorp, 
Thermo Scientific). After washing with PBS, surface of the wells were coated with 1% 
(w/v) bovine serum albumin in PBS supplemented with 0.05% Tween-20 at 4°C 
overnight. 5 pmol of biotinylated-GST was immobilized on it, and unbound protein was 
washed. Approximately 2.0 × 1010 PFU of the T7 phage was dissolved in tris-buffered 
saline supplemented with 0.5% Triton X-100, and applied to the well plate. The plate 
was incubated for 1 hour at 25 °C with shaking by using a maximizer (MBR-022UP, 
Taitec, Japan), and then washed three times with tris-buffered saline supplemented with 
0.5% Triton X-100. The bound phage was incubated with T7 tail fiber monoclonal 
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antibody (1:5,000 dilution, Merck Millipore) and anti-mouse IgG HRP-linked antibody 
(1:5,000 dilution, Cell Signaling) for 1 hour at 25 °C with shaking. After washing, 
o-phenylenediamine dihydrochloride substrate (SigmaFast OPD, Sigma Aldrich) was 
added, and the absorbance was quantified using a microplate reader equipped with a 
450 nm band-pass filter (Bio-Rad). 
 
GST-binding peptide synthesis and fluorescence polarization assay 
A peptide (acetyl-R-M-W-C-T-H-D-G-Y-OH) was synthesized and characterized by 
HPLC and ESI-TOF-MS by GenScript Corp (USA). A mock peptide 
(H2N-K-N-F-F-W-K-T-F-T-S-C-D-Y-K-D-D-D-D-K-OH) was synthesized and used in 
a previous study.7 Purity of the peptide was estimated to be above 95%. For the 
conjugation of tetramethylrhodamine (TMR) or nitrobenzofurazan (NBD), alkylating 
reagent and neutralized TCEP (pH 7) were mixed with the peptide (100 µM) in a 
phosphate buffer (20 mM phosphate-KOH, pH 7.4) at final concentrations of 150 µM 
and 500 µM, respectively. 5-TMRIA (Tetramethylrhodamine-5-Iodoacetamide; cat. No. 
T-6006) and IANBD amide 
(N,N'-Dimethyl-N-(iodoacetyl)-N'-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)ethylenediamine; 
cat. No. D-2004) were purchased from Molecular Probes. The mixture was incubated 
overnight at 37 °C in the dark with shaking. After addition of formic acid at a final 
concentration of 1%, the TMR-conjugated peptide was purified with reverse-phase 
HPLC (Shimadzu, Japan) equipped with a XTerra Prep MS C18 column (10 × 50 mm, 
Waters). The peptide was separated using a 0-100% linear gradient of acetonitrile 
containing 0.1% trifluoroacetic acid during 12 min at a flow rate of 4 ml per a minute. 
Fractions containing the TMR-conjugate peptide Ire lyophilized and then dissolved in 
dimethyl sulfoxide. Peptide concentrations were calculated by absorption peak at 280 
nm. Characterization of the peptides was performed by LC-MS (see above; Fig. S1). 
Purity was estimated to be above 90%. 
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Figure S1. LC-MS analysis of chemically synthesized peptides. (A) unmodified 
Ac-R-M-W-C-T-H-D-G-Y-OH peptide (equivalent to the T7 phage clone 5 in Fig. 3B and S7). (B) 
TMR-conjugated peptide. (C) NBD-conjugated peptide. (D) unmodified unrelated peptide.7 (E) 
TMR-conjugated unrelated peptide. Chemical structures of TMR and NBD are shown in below. 
 
Fluorescence polarization was measured with a HYBRID-3000ES (Photoscience, 
Japan) equipped with appropriate filters (TMR: Ex. 535/540 nm and Em. 570 nm, NBD: 
Ex. 480 nm and Em. 530 nm). The fluorophore-conjugated peptide (4 pmol, 20 nM) 
was incubated with various concentrations of GST or BSA in phosphate-buffered saline 
at 30°C. Klotz plot was generated by GraphPad Prism software 6.0 (GraphPad Software, 
San Diego, CA), and the sigmoid curve was fitted with non-linear least squares analysis 
to obtain the dissociation constant.  
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CHAPTER 3 
 
Construction of a salicylic 
acid-conjugated peptide library and 
selection of streptavidin-binders   
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n Abstract 
 
I have achieved site-specific conjugation of several haloacetamide derivatives into 
designated cysteines on bacteriophage T7-displayed peptides, which are fused to T7 
capsid protein gp10. This easiest gp10 based-thioetherification (10BASEd-T) undergoes 
almost quantitatively like a click reaction without side reaction or loss of phage 
infectivity. The post-translational modification yield, as well as the site-specificity, is 
quantitatively analyzed by a fluorescent densitometric analysis after gel electrophoresis. 
The detailed structure of the modified peptide on phage is identified with tandem mass 
spectrometry. Construction of such peptide-based phage library displaying non-natural 
structures will be useful for future drug discovery. For this aim, I propose a novel 
concept of pharmacophore generation from a drug-like molecule (i.e., salicylic acid) 
conjugated with randomized peptide. By using the hybrid library, streptavidin-specific 
binders are isolated through 4 rounds of biopanning. 
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n 3.1  Introduction 
 
Recently, post-translational chemical modification of bacteriophage (referred to 
hereafter as phage)-displayed peptides is attracting attention for drug discovery.1, 2 A 
pioneer work of the non-natural peptide/protein library construction on phage was 
reported in 2004; a fluorogenic biosensor was developed by conjugating a fluorophore 
with a designated Cys at the antigen-binding site of antibody library on the phage.3 
Until now, multiple research groups have reported construction of non-natural peptide 
libraries by the post-translational chemical modifications of M13 phage-displayed 
peptides.2, 4-9 Another type of phage, T7, is also used for phage display,10, 11 and 
superior to the M13 phage in view of bias and handling.12 Very recently, I have 
constructed a non-natural peptide library by the post-translational chemical 
modification of T7 phage-displayed peptides, namely gp10 based-thioetherification 
(10BASEd-T).13 The 10BASEd-T is carried out in one-pot without side reactions or loss 
of phage infectivity; the reaction efficiency and site/position specificity of the 
10BASEd-T on the T7 phage were as excellent as those of (chemo)enzymatic or click 
introduction of functional groups on proteins. By using a tetramethylrhodamine 
(TMR)-conjugated library via the 10BASEd-T, glutathione S-transferase 
specific-binders have been discovered.  
A potential limitation of this library is that the TMR moiety is too bulky and 
hydrophobic, which may cause non-specific binding or aggregation of the binders. Thus, 
I envision that conjugation of a water-soluble and small drug-like molecule, instead of 
TMR, to a peptide library would increase the possibility to discover target-specific 
binders. Here I attempt a novel concept of a pharmacophore generation by conjugation 
of a drug-like molecule to a randomized library peptide via the 10BASEd-T (Scheme 1). 
As the model drug-like molecule, commercially available 4-iodoacetamidosalicylic acid 
(Sal-IA) was used because it is one of the smallest pharmaceutical molecules possessing 
both hydrophobic benzene ring and hydrophilic hydroxyl / carboxyl groups. These 
groups may potentially interact with various proteins through hydrophobic / pi 
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interactions and hydrogen bonding,14 and seldom form aggregates.15 If surroundings of 
the drug-like molecule are optimized for interaction with target biomolecules of interest, 
novel specificity and affinity would be generated. Thus, I constructed the artificial 
peptide library possessing a salicylic acid (Sal) moiety via the 10BASEd-T. 
 
 
Scheme 1.  Construction of a peptide-fused pharmacophore library with a model 
drug-like (i.e., salicylic acid; Sal) core structure via the 10BASEd-T. 
 
 
Scheme 2.  Thioetherification of SH-group on peptide by SN2 reaction. 
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n 3.2 Results and discussion 
 
For the optimization of site-specific introduction of Sal group via the 10BASEd-T, I 
mixed Sal-IA with various molar concentrations and a T7-displayed model peptide (1.0 
× 1011 PFU of the T7 phage) in 700 µL of phosphate-buffered saline (pH 7.4) 
supplemented with 500 µM tris(2-carboxyethyl)phosphine (TCEP) and 400 mM NaCl 
at 4 °C. After 3 hours reaction, the peptide was further treated with 
5-idodoacetamide-fluorescein (FL-IA; 200 µM) for 3 hours at 4 °C. The latter reaction 
with fluorescent FL-IA blocks all the unreacted SH-groups on the T7 phage-displayed 
peptide after the conjugation with Sal-IA. My study demonstrated that fluorescent 
tetramethylrhodamine-iodoacetamide is conjugated to at least 95% of T7 
phage-displayed peptide.13 Similarly, I confirmed that FL-IA was conjugated to at least 
95% of the displayed peptide when 200 µM of FL-IA was used for the modification 
(data not shown). Thus, I can indirectly estimate conversion yield of the Sal-IA 
conjugation by fluorescent densitometric analysis (Fig. 1A). After the 10BASEd-T, 
whole T7 phage proteins were subjected to sodium dodecyl sulfate poly-acrylamide gel 
electrophoresis (SDS-PAGE), followed by in-gel fluorescence imaging. When Sal-IA 
was absent in the reaction mixture, a single fluorescent band could be seen at an 
appropriate molecular weight (ca., 44 kDa) of the peptide-fused gp10 (Fig. 1B; upper 
panel, lane 2). This indicates that the alkylation with FL-IA exclusively occurred at the 
peptide-fused gp10. Note that neither protein components for the infection nor other T7 
phage molecules were included in the reaction.13 When the concentration of Sal-IA was 
increased, the fluorescent band disappeared. This indicates that the designated Cys on 
the displayed peptide had already reacted with Sal-IA, and FL-IA no longer reacted 
with the peptide. From the densitometric analysis, the optimal molar concentration of 
Sal-IA was around 800 µM; almost all the designated Cys on the peptide reacted with 
Sal-IA (Fig. 1C). Thus, I successfully established a quantification method of the 
10BASEd-T reaction in a visible manner, even if the introduced non-natural molecule 
does not possess any chromophores. Recently, Derda and co-workers demonstrated a 
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compatible quantification method, namely the biotin capture assay, to determine the 
chemical modification yield on M13 phage-displayed peptides.2, 7 In this method, biotin 
is once conjugated to the M13 phage-displayed peptides. Then, the biotin-conjugated 
M13 phage is captured by streptavidin-conjugated affinity beads and subjected to a 
plaque assay. This method might be useful when the amount of the modified phage is 
extremely limited. If it is sufficient, my quantification method shown above is rapid and 
straightforward. 
Under the optimized modification conditions, I examined the infectivity of the 
Sal-conjugated T7 phage peptide library by plaque assay and found that the modified 
T7 phage retained its infectivity (Fig. 2). This suggests that the T7 phage is an excellent 
platform for post-translational modifications. 
 
 
Figure 1. Optimization of Sal-IA concentration. (A) Procedure of the optimization. A T7 
phage-displayed model peptide was modified via the 10BASEd-T with various molar 
concentrations of Sal-IA under standard conditions (described in Materials and Methods). After 
the Sal-conjugation, the peptide was further modified via the 10BASEd-T with 200 µM of FL-IA. 
Equal amounts of phage proteins were subjected to SDS-PAGE followed by fluorescence 
imaging. Sal-IA and FL-IA represents salicylic acid- iodoacetamide and 
fluorescein-iodoacetamide, respectively. (B) In-gel fluorescence imaging after the gel 
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electrophoresis (upper panel). Total T7 phage proteins were stained with coomassie brilliant blue 
(CBB) (lower panel). (C) Percentages of Sal-unconjugated peptide in each concentration of 
Sal-IA. 
 
 
To achieve more precise characterization, I performed a mass spectrometric 
analysis of the Sal-conjugated peptide. MS analysis of the phage-displayed peptide is 
challenging because small amounts of peptides are obtained per batch.2 Similar to M13 
phage-displayed peptides fused to a minor coat protein pIII,16 relatively few copies (ca., 
10 molecules) of peptides are displayed per single T7 phage virion when a mid-copy 
phage display vector (T7Select10) is used.17 These protein amounts are nearly at the 
detection limit for MS-based characterization of the peptide.2 To bypass this problem, I 
generated a model T7 phage13 carrying approximately 200 molecules of the peptides per 
single virion by using a high-copy vector (T7Select415).18 In my study, I successfully 
analyzed TMR-conjugated peptides on the model T7 phage by conventional 
LC-MS/MS.13 After the 10BASEd-T with Sal-IA followed by SDS-PAGE, the 
peptide-fused gp10 band around 40 kDa in the gel was excised and digested with 
trypsin. The resulting peptide fragments were analyzed by LC-MS/MS. Two 
chromatographic peaks at 300-400 nm (Sal absorption) were detected (data not shown), 
and each of them was identified as the Sal-conjugated T7 phage-displayed peptide by 
tandem mass spectrometry (Fig. 3). Also these data suggest that two Sal molecules were 
conjugated to the two designated Cys on T7 phage-displayed peptides. At the same time, 
most of the other peptide fragments derived from gp10 were identified by peptide mass 
fingerprinting based on MS/MS ion search (data not shown). Very recently, mass 
spectrometric analysis of the modified M13 phage-displayed peptide was reported by 
using high-performance MS systems.19, 20 In future studies, not only qualitative but also 
quantitative mass spectrometric study of the modified phage-displayed peptide might be 
available. 
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Figure 2.  Infectivity of Sal-conjugated T7 phage library. A T7 phage library 
(-S-G-G-G-X3-C-X6-C-X3; X represents any randomized amino acid) was treated with or without 
salicylic acid-iodoacetamide (Sal-IA; 800 µM) in the presence of TCEP (500 µM) under standard 
conditions (see Experimental Section). The number of plaque forming units (PFU) was 
determined by a serial dilution method and plaque assay. The graph summarizes the results of 
three independent experiments. Error bars represent standard deviations. Statistical analysis 
was performed by unpaired Student’s t-test. n.s., not significant (p values = 0.40 [left] and 0.22 
[right], respectively). 
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Figure 3.  Introduction of Sal onto T7 phage-displayed peptide via the 10BASEd-T. Here, a 
model T7 phage carrying a high-copy vector was used. After the 10BASEd-T followed by 
SDS-PAGE, Sal-conjugated peptide-fused gp10 was excised and subjected to in-gel 
trypsinization followed by conventional LC-MS/MS analysis. Note that trypsin could not cleave 
before proline.13 MS and MS/MS spectra correspond to the trypsinized two peptide fragments 
possessing the Sal moiety. 
 
 
Figure 4. Schematic diagram of biopanning used in this study. (A) Construction of 
Sal-conjugated peptide library on T7 phage through the 10BASEd-T. (B) Incubation of the phage 
display peptide library with immobilized streptavidin. (C) Washing of unbound phage. (D) 
Amplification of the streptavidin-bound phage for subsequent rounds of biopanning. 
 
 
I next attempted to find target-specific binders from the Sal-conjugated peptide 
library as shown in Fig. 4. In advance of biopanning, a T7 phage library carrying 
X3-C-X6-C-X3 peptides (where X represents any amino acid), which had been generated 
from the mid-copy vector (T7Select10), were modified through the 10BASEd-T. To 
include the possibility that two alkylated cysteines may improve affinity toward the 
target protein, I conjugated two Sal-groups into a single library peptide. Four rounds of 
biopanning were performed against streptavidin as a model target protein. Enrichment 
of the streptavidin-binders were confirmed by plaque assay after the washing step in 
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biopanning; the population of streptavidin-bound T7 phage was increased through 
biopanning (Fig. 5A). Binding specificity to streptavidin was confirmed by 
enzyme-linked immunosorbent assay (ELISA). To examine whether the Sal but not the 
amide moiety is required for the binding, Sal-IA-treated and iodoacetamide (IA)-treated 
T7 phage were subjected to ELISA in parallel. After 4 rounds of biopanning, the 
Sal-conjugated T7 phage-displayed peptides showed the strongest binding to 
streptavidin (Fig. 5B), suggesting that the Sal moiety of the peptides played a crucial 
role in interaction with the target. Eight of the T7 phage monoclones were randomly 
chosen from the phage pool. Three of the streptavidin-bound monoclones were 
subjected to DNA sequencing analysis, whereas five of the clones did not bind to 
streptavidin. Two of the positive clones had the same sequence (clone 7; 
-A-M-W-C-Q-Y-H-P-Q-N-C-Y-K-M), and one was different (clone 2; 
-R-I-V-C-V-Q-H-P-Q-F-C-Q-Y) (Fig. 5C).  I also found that such clones had a 
consensus sequence of C*-X-X-H-P-Q-X-C* (C* and X represent alkylated Cys and any 
amino acid, respectively) (Fig. 5C, left panel), which contains the known 
streptavidin-binding sequence (H-P-Q).21, 22 However, this peptide on the T7 phage 
exclusively bound to streptavidin only when it was modified with Sal-IA. This means 
that the Sal moiety and the surrounding consensus peptide cooperatively enhanced the 
binding ability toward streptavidin, to generate a novel pharmacophore (Fig. 5C).  
To determine the binding affinity of the peptide to streptavidin by using a 
fluorescence polarization (FP) assay, I chemically synthesized a fluorescent peptide 
possessing the sequence of clone 7 
(K-5/6-FAM-A-M-W-C*-Q-Y-H-P-Q-N-C*-Y-K-M-NH2; C* represents Sal-conjugated 
Cys). The synthesized linear peptide bound to streptavidin in a protein-specific manner 
(Fig. 6A, left panel), which is consistent with a previous report that HPQ-containing 
peptide does not bind to non-glycosylated forms of chicken avidin (NeutrAvidin®).23 
The dissociation constant (KD) was estimated to be 180 nM. Usually, linear peptides 
bind to a target with a lower affinity than cyclic ones, because the latter rigid structures 
minimize conformational entropy loss associated with the binding.12, 24 Indeed, 
(C) 2014 Keisuke Fukunaga, All Rights Reserved. 
 59  
H-P-Q-containing cyclic peptides bind to streptavidin with a higher affinity.21, 25 
Nevertheless, the affinity of Sal-conjugated linear peptide was almost the same as that 
of the H-P-Q-containing cyclic peptide.25 To my knowledge, there is no 
streptavidin-binding linear peptide with submicromolar affinity; exceptionally, 
H-P-Q-containing 38-mer linear protein, SBP-tag, binds to streptavidin with high 
affinity (i.e., 2.5 nM).26 On the other hand, mock (Sal-unconjugated) peptide bound to 
streptavidin with a roughly 10-fold lower affinity under reducing conditions (Fig. 6A, 
right panel). This again suggests that the excellent pharmacophore was generated only 
when Sal was surrounded by the appropriate peptide.  
H-P-Q-containing peptides are usually biotin-mimetics,21 thus I examined whether 
the Sal-conjugated peptide binds to streptavidin in the same manner. As expected, 
interaction of the Sal-conjugated peptide with streptavidin was fully disrupted by biotin 
(Fig. 6B), suggesting that the peptide binds to the biotin-binding site of streptavidin. 
In conclusion, site-specific conjugation of haloacetamide derivatives to the 
designated Cys on bacteriophage T7-displayed peptides was achieved. This underwent 
almost quantitatively without side reaction. The structure of the modified peptide on 
phage was identified with tandem mass spectrometry, and the conjugation yield was 
estimated by SDS-PAGE followed by fluorescence imaging in a rapid and universal 
manner. Generation of a novel pharmacophore by conjugation of a drug-like molecule 
to fully randomized peptide on T7 phage was also demonstrated. Recently, optimization 
of a pharmacophore by conjugation with library peptide via the mRNA-display and 
M13 phage display techniques were reported.8, 29 In both cases, the pharmacophore 
molecule has already been known to bind a target protein, and the binding ability was 
improved by in vitro selection. In contrast, I demonstrated that even optimization of a 
small drug-like molecule, which is never known to bind to a model target protein, could 
generate a novel pharmacophore. I envision that computer assisted de novo designing,30 
data mining from broad public databases,31 and/or docking simulation of the small 
drug-like molecule31, 32 followed by optimization of its surroundings by peptide via the 
10BASEd-T will be a general technology for drug discovery.  
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Figure 5. (A) Enrichment of streptavidin (SA)-coupled beads-bound T7 phage through 
biopanning. PFU (plaque forming units) and R indicate the number of the beads-bound T7 phage 
and rounds of biopanning, respectively. (B) ELISA of modified T7 phage polyclones against 
streptavidin or bovine serum albumin (BSA). BSA was used as a negative control to examine 
non-specific binding. Sal-IA and IA indicate salicylic acid-iodoacetamide and iodoacetamide, 
respectively. Error bars represent standard deviations of three independent experiments. (C) 
ELISA of two types of T7 phage monoclones randomly chosen from the phage pool after 4 
rounds of biopanning. The peptide sequences displayed on the phage are shown in the right 
panel. A consensus sequence is highlighted. An asterisk indicates the modified cysteine. For the 
alignment, ESPript program (http://espript.ibcp.fr/)27 was used. A negative control experiment 
(blank) was also performed in the absence of T7 phage.  
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Figure 6. (A) Determination of streptavidin-binding affinities of the Sal-conjugated peptide (left 
panel) and the mock peptide (right panel) by fluorescence polarization assay. The amino acid 
sequence of the peptide is shown in the upper part. The plots indicate the polarization (mP) of 
the fluorophore (FAM)-coupled peptides in the presence of various concentrations of target 
proteins. NeutrAvidin and bovine serum albumin (BSA) were used as mock target proteins. (B) 
Competitive binding assay. Biotin as a competitor was mixed with the Sal-conjugated 
peptide-streptavidin complex. Error bars represent standard deviations. 
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n 3.3 Additional figures and experimental procedures 
 
 
Figure S1.  Identification of peptide fragments derived from fluorescein (Flu)-conjugated T7 
phage-displayed peptide by LC-MS/MS. Upper panel: 450 nm (Flu absorption under low pH 
condition) chromatogram of the trypsinized peptide-fused gp10. Note that trypsin could not 
cleavage before proline. Middle and lower panels: MS and MS/MS spectra correspond to the 
trypsinized two peptide fragments possessing Flu moiety. 
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Figure S2.  Mass spectrometric analysis of chemically synthesized peptides. MS spectra of 
mock peptide (upper panel) and Sal-conjugated peptide (lower panel). 
 
General  
All experiments were performed with commercially available reagents and kits. 
Note that no special materials and skills are needed. Contrary to popular belief and the 
T7Select system manual (Merck Millipore), CsCl step gradient and ultracentrifugation 
are not necessary to perform all of the experiments to obtain a target-specific binder. 
For purification of T7 phage at every step by polyethyleneglycol / NaCl precipitation, I 
only used a conventional centrifugation system which can rotate at 13,000 rpm. In all 
phage display experiments, Escherichia coli BLT5403 cells were used. Note that 
medium-high-copied peptide display (200 peptides per virion) is produced by an 
amplification of T7 phage carrying a T7Select415-1b high-copy vector by using 
BLT5403 cells.13, 18 
 
Construction of T7 phage display libraries 
A T7 phage display peptide library (-S-G-G-G-X3-C-X6-C-X3; X represents any 
amino acid) was independently constructed in the same manner of my method.10, 11, 13 
 
Chemical modification of T7 phage-displayed peptide via the 10BASEd-T  
Procedures of standard reaction conditions of the 10BASEd-T are the following. 
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Tris(2-carboxyethyl)phosphine (TCEP) and 4-iodoacetamidosalicylic acid (Sal-IA; MP 
Biomedicals, cat. No. 102065) stock aqueous solutions of pH 7 should be prepared by 
neutralization with NaOHaq in advance. All reactions were carried out in 1.5 mL 
microcentrifuge tubes. T7 phage particles (approximately 1.0 × 1011 PFU) were 
resuspended in 700 µL of phosphate-buffered saline (PBS; Nacalai tesque, cat. No. 
14249-95) supplemented with 400 mM NaCl, and well dissolved by vortex. At this step, 
the solution contained 1.0 × 1012 (T7 phage made by T7Select10-3b system for the 
selection) or 2.0 × 1013 (by T7Select415-1b system for the optimization of Sal-IA 
concentration) molecules of the T7-displayed peptides. After centrifugation at 12,000 
rpm for 5 minutes at room temperature, the supernatant was mixed with neutralized 
TCEP-NaOH (final concentration of 500 µM) at 4 °C.  
 
For the selection against streptavidin: Neutralized Sal-IA-NaOH was added to the 
above TCEP-treated phage at a final concentration of 800 µM, and the mixture was 
incubated at 4 °C for 3 hours in the dark with shaking. To inactivate the unreacted 
Sal-IA, 2-mercaptoethanol was added to the mixture at a final concentration of 5 mM, 
and further incubated at 4 °C for several minutes. The T7 phage particles were 
precipitated with a mixture of polyethylene glycol 6000 (Nacalai tesque) and sodium 
chloride to final concentrations of 5% (w/v) and 0.5 M, respectively. After 
centrifugation, the precipitate was dissolved in an appreciate buffer. 
 
For the optimization of Sal-IA concentration: Neutralized Sal-IA-NaOH was added 
to the above TCEP-treated phage at various concentrations, and the mixture was 
incubated at 4 °C for 3 hours in the dark with shaking. After the reaction, 
5-iodoacetamide-fluorescein (FL-IA) stock solution in dimethyl sulfoxide/water (1:1 by 
volume) was added at a final concentration of 200 µM, and the mixture was further 
incubated at 4 °C for 3 hours. FL-IA was purchased from Sigma-Aldrich (cat. No. 
I9271). The latter reaction with fluorescent FL-IA reacts with all the unreacted 
SH-groups on the displaying peptide after the conjugation with Sal-IA. Thus, I can 
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indirectly estimate conversion yield of the Sal-IA treatment by SDS-PAGE followed by 
densitometric fluorescence analysis of the peptide-fused gp10. Site-specificity of the 
10BASEd-T by using FL-IA was confirmed by LC-MS/MS (Fig. S1). For the 
optimization, a model T7 phage with medium-high-copied peptides possessing the 
-G-S-R-V-S-C-G-G-R-D-R-P-G-C-L-S-V sequence at the C-terminal region of gp10 
was used.13 
 
 
Chemical structure of 5-iodoacetamide-fluorescein 
 
In-gel fluorescence imaging 
T7 phage particles were dissolved in 1 × sample buffer (62.5 mM 
tris(hydroxymethyl)aminomethane-HCl, pH 6.8, 10% glycerol, 2% SDS, 5% 
2-mercaptoethanol, 0.002% bromophenol blue). The solution was incubated at 95 °C for 
5 min, and then subjected to SDS-PAGE. Proteins were resolved by a 10% 
polyacrylamide gel. After electrophoresis, the FL-conjugated proteins were visualized 
by in-gel fluorescence imaging using a conventional gel imager (ChemiDoc XRS+, 
Bio-Rad) excited with UV light.  
 
Mass spectrometric analysis 
For mass spectrometric analysis, a PAGE gel was stained with Rapid Stain CBB 
kit (Nacalai tesque, cat No. 30035-14). The stained protein bands were excised from the 
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gel. Proteins in the gel were reduced with 25 mM dithiothreitol at 65 °C for 10 min, and 
then alkylated with 55 mM iodoacetamide at room temperature for 60 min in the dark. 
Digestion was carried out with modified trypsin (Promega, Madison, WI) at 37 °C 
overnight. The resulting peptides were analyzed using Agilent 1100 semi-micro HPLC 
system (Agilent Technologies) equipped with a C18 reverse-phase column (Hypersil 
GOLD, 2.1 × 100 mm, Thermo Scientific) connected to LCQ-Fleet mass spectrometer. 
The peptides were separated using a 0-50% gradient of acetonitrile containing 0.1% 
formic acid during 40 min at a flow rate of 300 µL per minute, and then eluted peptides 
were directly sprayed into the mass spectrometer. The mass spectrometer was operated 
in the data-dependent mode and externally calibrated. Survey MS scans were acquired 
in the 300-2000 or 400-2000 m/z ranges. Multiply charged ions of high intensity per 
scan were fragmented with collision-induced dissociation in the ion trap. A dynamic 
exclusion window was applied within 30 seconds. All tandem mass spectra were 
collected using normalized collision energy of 40%. Data were acquired and analyzed 
with Xcalibur software v. 2.07 (Thermo Scientific).   
 
Biopanning against streptavidin 
For biopanning, approximately 8.4 × 1010 PFU of a T7Select10 library 
(-S-G-G-G-X3-C-X6-C-X3; X represents any randomized amino acid) were modified via 
the 10BASEd-T. The modified T7 library was dissolved in a selection buffer (PBS 
supplemented with 0.5% Triton X-100 and 1 mM TCEP-NaOH), and incubated with 
streptavidin-immobilized nanomagnetic beads (FG streptavidin beads, Tamagawa Seiki, 
cat No. TAS8848N1170) at 4 °C. The beads were washed three times with 200 µL of 
the selection buffer, and the streptavidin-bound phages were directly infected and 
amplified with E. coli BLT5403 cells. Stringent conditions were applied to each round 
by shortening the binding time and by increasing the washing frequency. For binding 
and washing, an automated bioscreening machine for phage display system 
(TargetAngler 8, Tamagawa Seiki) was used. After 4 rounds of biopanning, randomly 
chosen T7 phage clones were subjected to DNA sequencing.  
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Enzyme-linked immunosorbent assay (ELISA) 
830 pmol of streptavidin (Wako Pure Chemical Industries) was dissolved in PBS, 
and immobilized on each well of a 96-well immunoplate (Nunc MaxiSorp, Thermo 
Scientific). After washing with PBS, surface of the wells were coated with 1% (w/v) 
BSA in PBS supplemented with 0.05% Tween-20 at 4°C overnight. Approximately 2.0 
× 1010 PFU of the T7 phage was suspended in a wash buffer (tris-buffered saline 
supplemented with 0.5% Triton X-100), and applied to the well plate. The plate was 
incubated for 1 hour at 25 °C with shaking by using a maximizer (MBR-022UP, Taitec, 
Japan), and then washed three times with the same buffer. The bound phage was 
incubated with T7 tail fiber monoclonal antibody (1:5,000 dilution; Merck Millipore, 
cat No. 71530-3) and anti-mouse IgG HRP-linked antibody (1:5,000 dilution; Cell 
Signaling, cat No. 7076) for 1 hour at 25 °C with shaking. After washing, 
o-phenylenediamine dihydrochloride substrate (SigmaFast OPD; Sigma Aldrich, cat No. 
P9187) was added, and the absorbance was quantified using a microplate reader 
equipped with a 450 nm band-pass filter (Bio-Rad).  
 
Peptide synthesis 
An unmodified fluorescent peptide 
(H2N-K-5/6-FAM-A-M-W-C-Q-Y-H-P-Q-N-C-Y-K-M-NH2) was prepared by solid 
phase peptide synthesis using a semi-automated personal synthesizer (PetiSyzer®; 
HiPep Laboratories, Japan) as described previously.28 Fmoc amino acids and 
Fmoc-Lys(5/6-FAM) were purchased from HiPep Laboratories and AAT Bioquest, 
respectively. The solid phase synthesis was performed on Fmoc-NH-SAL-PEG resin 
(Watanabe Chemical Industries, LTD., cat No. A00213). Chain elongation was carried 
out by using 1-Hydroxy-7-azabenzotriazole (HOAt) and 
N,N,N',N'-tetramethyl-O-(7-azabenzo-triazol-1-yl)uronium hexafluorophosphate 
(HATU) as the coupling reagent in the presence of diisopropylethylamine (DIPEA) / 
N,N-dimethylformamide (DMF) / N-Methylpryrrolidone (NMP). The coupling was set 
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to 50 °C for 40 minutes. The resin-bound peptide was cleaved by trifluoroacetic acid 
(TFA) / water / triisopropylsilane (TIS) / 1,2-ethandithiol (EDT) (94/ 2.5/ 1/ 2.5 
(v/v/v/v)) for 1 hour at 50 °C. The crude peptide was dissolved in 0.1% formic acid (aq) 
and then purified with reverse-phase HPLC (Shimadzu, Japan) equipped with XTerra 
Prep MS C18 column (10 × 50 mm, Waters) and XBridge Prep C18 column (10 × 50 mm, 
Waters). The peptide was separated using a 0-100% linear gradient of acetonitrile 
containing 0.1% formic acid during 12 min at a flow rate of 4 mL per minute. 
Characterization of the peptides was performed by LC-MS/MS (Fig. S2). Purity was 
estimated to be above 95%. For the conjugation of Sal, the neutralized alkylating 
reagent (Sal-IA-NaOH) and neutralized TCEP (pH 7) were mixed with each peptide 
(100 µM) in a phosphate buffer (20 mM phosphate-KOH, pH 7.4) at final 
concentrations of 1 mM and 500 µM, respectively. The mixture was incubated 
overnight at 37 °C in the dark with shaking. After addition of formic acid at a final 
concentration of 2%, the peptide was purified with reverse-phase HPLC. Purity was 
estimated to be above 90%. 
 
Fluorescence polarization assay 
Fluorescence polarization was measured with a HYBRID-3000ES (Photoscience, 
Japan) equipped with appropriate filters (Ex. 480 nm and Em. 535/40 nm). The 
Sal-conjugated fluorescent peptide (4 pmol) was incubated with various concentrations 
of streptavidin, NeutrAvidin, or bovine serum albumin (BSA) in tris-buffered saline (50 
mM Tris-HCl, pH 8.0, 150 mM NaCl) supplemented with 1 mM TCEP-NaOH at 30°C. 
Concentration of the fluorescent peptide was determined by absorption coefficient at 
495 nm. NeutrAvidin® and BSA were purchased from Thermo Scientific and Nacalai 
tesque, respectively. Concentrations of streptavidin and NeutrAvidin were determined 
by absorption coefficient at 280 nm. Concentration of BSA was determined by Bradford 
protein assay (Bio-Rad). Klotz plot was generated by GraphPad Prism software 6.0 
(GraphPad Software, San Diego, CA), and the sigmoid curve was fitted with non-linear 
least squares analysis to obtain the dissociation constant. For the negative control 
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experiment, the Sal-unmodified fluorescent peptide (4 pmol) was used for the 
fluorescence polarization assay with the same procedure described above. For the 
competitive binding assay, various concentrations of biotin were added to the solution 
containing Sal-conjugated peptide-streptavidin complex (4 pmol of the peptide and 3 
nmol of streptavidin; 20 nM and 15 µM, respectively). Biotin was purchased from New 
England Biolabs. 
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CHAPTER 4 
 
Construction of a crown ether-like 
macrocyclic library and selection of 
Hsp90-binders 
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n Abstract 
 
By using the 10BASEd-T, crown ether-like macrocyclic library possessing 
randomized peptide is synthesized on bacteriophage T7. Among 1.5 × 109 diversity of 
the supramolecules, the Hsp90 N-terminal domain-specific binder is discovered. 
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n 4.1 Introduction 
 
Macrocyclic artificial supramolecules (e.g., cyclophanes,1 rotaxanes,2 calixarenes,3-5 
porphirins,6,7 and fullerene adducts8) have been attracting attentions for broad 
applications such as biomedical, electrochemical, and photophysical materials. Among 
them, crown ethers and these analogues9, 10 possess biocompatibility because 
hydrophilic oligoethylene structure increases water solubility, hence prevents 
aggregation. The ether oxygen atoms would form hydrogen bondings with basic amino 
acids of protein.11 Despite the potential usefulness of the crown analogues, 
comprehensive study for biological application, such as discovery of target 
protein-specific binders, has never been reported. It is most plausibly because that 
structural diversities of the rationally designed analogues are too small to find strong 
binders toward the complex biomolecules. To increase diversity of the crown analogues, 
combinatorial synthetic approach is often used.12 Nevertheless, the size of the library is 
far enough. 
Recently, I have established a library construction system by conjugation between 
artificial molecules and randomized library peptides; the site-specific conjugation at 
designated cysteines in the randomized peptide region on a capsid protein (gp10) of T7 
phage has been achieved.13 This gp10 based-thioetherificaion (10BASEd-T) is carried 
out in one-pot without side reactions or loss of phage infectivity. By using the 
10BASEd-T, here I cyclized both ends of oligoethyleneglycol unit by randomized 
peptide via the thioether linkage, to afford the crown analogue library with vast 
diversity (i.e., 109). 
(C) 2014 Keisuke Fukunaga, All Rights Reserved. 
 75  
 
Scheme 1.  (A) Chemical structure of EBB: 1. (B) Construction of a crown ether-like 
macrocyclic library through the 10BASEd-T. X represents randomized amino acid. 
 
 
 
Scheme 2.  Thioetherification of SH-groups on peptide by SN2 reaction. 
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■	 4.2 Results and discussion 
 
I synthesized a cysteine-reactive bifunctional synthon, 
N,N’-[1,2-ethanediyl-oxy-2,1-ethanediyl]bis(2-bromoacetamide) (EBB; Scheme 1A) as 
the supramolecule core, and the 10BASEd-T was performed as follows (Scheme 1B) : 
T7 phage-displayed peptides (1.0 × 1011 PFU) were mixed with EBB in 700 µL of 
phosphate-buffered saline (pH 7.4) supplemented with 500 µM 
tris(2-carboxyethyl)phosphine (TCEP) and 400 mM NaCl. After 3 hours reaction at 
4 °C, 2-mercaptoethanol (5 mM) was added to quench unreacted EBB, and the mixture 
was incubated for 5 min at 4 °C. To confirm the cyclization of the synthon with T7 
phage-displayed peptide linker, I used a model phage displaying  linker peptides 
(-G-S-R-V-S-C-G-G-R-D-R-P-G-C-L-S-V).13 After the 10BASEd-T against the model 
T7 phage, total proteins were subjected to sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis followed by coomassie brilliant blue staining. The linker-fused T7 
capsid protein (gp10) was excised from the gel, and then digested with lysyl 
endopeptidase. The resulting peptide fragments were analyzed by LC-MS/MS. MS and 
MS/MS results indicate that Cys in the model T7 phage-displayed peptide linker were 
site-specifically conjugated with EBB (Fig. S1). Generally, acquisition of a MS/MS 
spectrum of a ring-forming peptide region is difficult.14, 15 However, I tried in-depth 
mass spectrometric analysis of the crown analogue on T7 phage, to clarify amino acid 
sequence of the ring-forming peptide region. Here I performed a LC-MS/MS analysis of 
the macrocycle by enzymatic digestion of the ring-forming peptide (Fig. 1A). After 
cleavage of the ring by trypsinization, the resultant branched peptide fused to both ends 
of EBB was analyzed by LC-MS/MS. Two classes of fragment ions were detected in 
the MS/MS analysis, and consistent with amino acid sequence inside the ring (Fig. 1B). 
Consequently, the model crown analogue on T7 phage was unambiguously identified. 
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Figure 2.  (A) Strategy for identification of a model crown analogue displayed on T7 phage. A 
T7 phage-displaying model linker peptide was conjugated with EBB via the 10BASEd-T, and then 
separated into a subunit by SDS-PAGE. After coomassie brilliant blue (CBB) staining, the 
asterisk corresponding to the crown-fused gp10 was excised and subjected to in-gel 
trypsinization followed by LC-MS/MS analysis. Arrows indicate trypsin cleavage site. (B) MS 
analysis of the ring-opening crown analogue. Above panel: MS spectrum. A series of multiple 
charged ions (circles) were detected, and consistent with theoretical m/z values of the crown 
analogue. Other ions were considered as trypsinized gp10 fragments (m/z 946.2, 631.1 and 
473.6: D-Q-A-A-Y-L-A-P-G-E-N-L-D-D-K-R-K, m/z 716.4: D-L-A-L-E-R). Lower panel: MS/MS 
spectrum. Trypsin could not cleave arginine C-terminus before proline as reported previously.8 
 
 
As a target of biopanning using the crown analogue library, I used heat shock 
protein 90 (Hsp90), which plays a crucial role in protein homeostasis, cell signaling, 
and stress response.16-18 Hsp90 is a highly conserved molecular chaperone which 
governs cellular protein quality control,19, 20 and considered as an important class of 
drug target in cancer therapy.21, 22 Prior to biopanning, EBB was cyclized with T7 
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phage-displayed peptide linker library (-S-G-G-G-X3-C-X7-C-X3; where X represents 
any amino acids)13, 23 via the 10BASEd-T as shown in Scheme 1B. Next, I examined the 
infectivity of the modified T7 phage library by plaque assay, and the infectivity titer 
was fully retained (Fig. S2).  
Six rounds of biopanning were performed against biotinlylated-Hsp90, and 
enrichment of Hsp90 binders was assessed by enzyme-linked immunosorbent assay 
(ELISA). After the 6 rounds of biopanning, the crown analogues on T7 phage 
polyclones showed the strongest binding to Hsp90, whereas ones lacking the crown 
core structure did not (Fig. S3A). Among 11 of randomly chosen T7 phage monoclone, 
10 clones had the same linker sequences, 
-R-S-W-C*-R-K-S-R-K-N-S-G-G-G-L-V-W-C*-F (Cys are conjugated with EBB) (Fig. 
S3B). This was an unexpected result, because the initial library was designed to be 
displaying -X3-C-X7-C-X3 peptide linkers; DNA sequencing of monoclones randomly 
chosen from the initial library supported that the peptide linkers were correctly encoded 
with no bias (data not shown). Thus, I speculate that trace amounts of the crown 
analogue with the longer peptide linker, which might be encoded by misligated DNA 
fragment, was enriched by biopanning. To confirm the effect of a crown moiety for the 
binding, biopanning by using the naïve cyclic peptide library with conventional 
disulfide (S-S) bridge (Scheme 1B, upper) was also performed. By sequence analyses, 
most abundant sequence -R-M-T-C*-Y-D-K-Q-H-H-H-C*-E-T-W (C* forms 
intramolecular disulfide bond) was obtained (Fig. S4B). This peptide also bound to 
Hsp90 NTD (data not shown), however the sequence was completely different from 
what was discovered from the crown-ether like supramolecule library; only N-terminal 
arginine and C-terminal hydrophobic aromatic amino acid (tryptophan) were identical. 
This indicates that the crown moiety strongly affects geometry of the whole macrocycle 
structure of the naïve library, to generate a novel supramolecular library. 
 Next, I examined the crown analogue-binding site of Hsp90. Hsp90 is structurally 
divided into three domains: N-terminal (NTD), middle (MD), and C-terminal (CTD) 
domains (Fig. 2A).24 Using each glutathione S-transferase (GST)-fused Hsp90 
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domain,25 GST-pull down assay was carried out. I found that the crown ether analogue 
on T7 phage monoclone exclusively bound to the NTD of Hsp90 (Fig. 2A). To 
determine affinity of the Hsp90 NTD-binding crown analogue, I synthesized the linker 
peptide with solid-phase peptide synthesis followed by cyclization with EBB core. 
Isothermal titration calorimetry (ITC) measurement was performed to obtain the 
dissociation constant (KD) as well as thermodynamic parameters. The crown analogue 
bound to GST-Hsp90 NTD with the KD value of 1.7 ± 0.5 µM, whereas the linker 
peptide itself almost did not (Fig. 2B). This suggests that both structures of the crown 
moiety and the rest peptide linker are essential for the Hsp90-specific binding. Also, 
favorable enthalpy change (ΔH) was observed, suggesting that hydrogen bonding and 
van der Waals force contributes to the interaction between the crown analogue and 
Hsp90 NTD. To investigate secondary structure of the macrocycle, circular dichroism 
(CD) spectroscopy was performed. CD spectrum showed that the crown analogue has a 
disordered structure (Fig. S5). This structural flexibility of the crown analogue might be 
important in the interaction, because Hsp90 recognizes unfolded substrates.19  
Geldanamycin (GA) is an anticancer natural product,21, 22 which binds to the 
ATP-binding pocket on the NTD of Hsp90.24 I here examined whether the crown 
analogue competes with GA for the Hsp90 NTD-binding. Using a 
fluorescein-5-isothiocyanate labelled GA (GA-FITC), fluorescence polarization (FP) 
competition assay was performed. Interaction between GA-FITC and GST-Hsp90 NTD 
was disrupted in the presence of non-labelled geldanamycin in a concentration 
dependent manner (Fig. S6B). On the other hand, the interaction was not inhibited in 
the presence of the crown analogue, suggesting that the macrocycle did not bind to the 
ATP-binding pocket. Almost all reported Hsp90 inhibitors are ATP competitors.21 Thus, 
the crown analogue will possibly be a novel Hsp90 inhibitor with a different inhibition 
mechanism, such as celastrol, which is an Hsp90 NTD-binding natural terpenoid.26  
 In conclusion, I demonstrated the first example to construct a supramolecular 
library with vast diversity on T7 phage, and successfully found a target protein-specific 
binder. Enthalpy change was strongly contributed to the binding between the discovered 
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crown analogue and the Hsp90 NTD. I envisage that discovery of functional 
supermolecules will be accelerated by the ensemble of rationally-designed artificial 
supramolecule cores and genetically-encoded random (poly-)peptide linkers. In parallel 
with finding the crown-based binders for different target biomolecules, I am now trying 
to construct a novel artificial libraries of multicyclic structures to find supramolecules 
with greater binding affinity. 
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Figure 2. (A) GST pull-down assay. EBB-modified T7 phage monoclone 
(-R-S-W-C*-R-K-S-R-K-N-S-G-G-G-L-V-W-C*-F; *Cys were conjugated with EBB core) was 
used as the input. N-terminal (NTD), middle (MD), and C-terminal (CTD) domains of Hsp90 are 
schematically shown on the left. (B) Isothermal titration calorimetry profiles of titrations of 
GST-Hsp90 NTD with crown analogue (left) and linear linker possessing the same peptide 
sequence (right). N: number of binding sites, KD: dissociation constant, ΔH: enthalpy change, 
ΔS: entropy change. 
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n 4.3 Additional figures and experimental procedures 
 
Figure S1. Tandem mass spectrometric analysis of the crown analogue displayed on T7 phage. 
(A) A model T7 phage monoclone modified by 10BASEd-T was separated into subunits by 
SDS-PAGE. After coomassie brilliant blue staining (left panel), the protein band corresponding to 
the crown molecule-fused gp10 (asterisk) was excised and subjected to in-gel lysyl 
endopeptidase (Lys-C) digestion followed by LC-MS/MS analysis. A blue arrow indicates the 
Lys-C cleavage site. (B) MS spectrum (left panel). A series of multiple charged ions (circles) 
were detected, and consistent with calculated m/z values of the crown molecule. MS/MS 
spectrum (right panel). 
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Figure S2. Infectivity of modified T7 phage. A T7 phage library (-S-G-G-G-X3-C-X7-C-X3; X 
represents any randomized amino acid) was treated with or without EBB (500 µM) in the 
presence of TCEP (500 µM) under the standard conditions. The number of plaque forming units 
was determined by a serial dilution method and plaque assay. The graph summarizes the results 
of three independent experiments. Error bars represent standard deviations. Statistical analysis 
was performed by unpaired Student’s t- test. n.s., not significant. 
 
 
 
Figure S3.  Biopanning against Hsp90 using the crown ether-like supramolecular library 
(-S-G-G-G-X3-C*-X7-C*-X3; Cys are conjugated with EBB). (A) T7 phage polyclones after each 
round (R) of the biopanning were modified with EBB. Both the modified and unmodified T7 
phage polyclones were subjected to ELISA. Bovine serum albumin (BSA) served as a mock 
protein. (B) T7 phage monoclones were chosen from phage pool after the 6 rounds of the 
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biopanning, and then subjected to DNA sequencing. Sequence logo was generated by WebLogo 
program.  
 
 
 
Figure S4. Biopanning against Hsp90 using the naïve T7 phage library 
(-S-G-G-G-X3-C-X7-C-X3). (A) ELISA result shows enrichment of Hsp90-binding phage through 6 
rounds of the biopanning. (B) Sequence alignment of Hsp90 binder (upper column) and 
non-binder (lower column). The alignment was generated by ESPript program 
(http://espript.ibcp.fr). Consensus sequences are highlighted. Frequency of each amino acid 
sequences are shown on the left side, and summarized into a sequence logo by WebLogo 
program. Hsp90-binding avidities are shown on right side. The consensus sequence was 
completely different from what was discovered in the Hsp90 NTD-binding crown molecule (Fig. 
S3B); only N-terminal arginine and C-terminal hydrophobic aromatic amino acid (tryptophan) 
were identical. 
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Figure S5.  CD spectra of Hsp90 NTD-binding crown molecule and synthetic peptide linkers. 
 
 
 
 
Figure S6. (A) Determination of Hsp90 N-terminal domain (NTD)-binding affinity of 
fluorophore-conjugated geldanamycin (GA) by FP assay. Middle domain (MD) and C-terminal 
domain (CTD) of Hsp90 were used as mock proteins for negative controls. Error bars represent 
standard deviations. The binding affinity of geldanamycin to Hsp90 NTD was close to a 
previously reported one.3 (B) Competitive binding assay. Non-labeled GA and mock peptide 
(GCDPETGTCG) served as a positive and negative control, respectively. The Hsp90 
NTD-binding crown molecule did not compete with GA-FITC, or possibly might enhance binding 
of GA-FITC to Hsp90. 
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Synthesis of EBB 
 
N,N’-[1,2-ethanediyl-oxy-2,1-ethanediyl]bis(2-bromoacetamide) (EBB; 1) was 
prepared as previously reported4 with minor modifications. Briefly, 
2,2’-(ethylenedioxy)bis(ethylamine) (25 mmol; cat. No. 385506, Sigma-Aldrich) and 
pottasium carbonate (60 mmol) were mixed in 100 mL of H2O/AcOEt = 1:1 solution. 
Then, bromoacetyl bromide (75 mmol; cat. No. B56412, Sigma-Aldrich) was added, 
and the mixture was stirred for 4 hours at room temperature. The organic layer was 
collected, and then the solvent was evaporated (860 mg: 81% yield). The crude reaction 
product (370 mg) was dissolved in pure water, and purified by reverse-phase middle 
pressure liquid chromatography (Yamazen ODS column 26 × 300 mm, flow rate 20 
mL/min with gradient 5-100% MeOH in pure water over 20 min). The fractionated 
sample was lyophilized (55% yield). ESI-IT-MS and 1H NMR (300 MHz, CDCl3) 
spectrum were shown in below (Fig. S7). 
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Figure S7. (A) MS spectrum (observed m/z values = 388.8, 390.8 and 392.8; calculated m/z 
values = 389.0, 341.0 and 393.0) and (B) 1H NMR spectrum of EBB. 
 
Construction of a crown ether-like supramolecular library via the 10BASEd-T  
Synthesis of the crown analogue on T7 phage was performed as described 
previously.5 Standard reaction condition of gp10 based-thioetherification (10BASEd-T) 
is the following: T7 phage particles (approximately 1.0 × 1011 PFU) were well 
suspended by sonication or vortex in a 700 μL of phosphate buffered saline (PBS) 
supplemented with 400 mM NaCl. After centrifugation at 12,000 rpm for 5 minutes at 
room temperature, the supernatant was mixed with neutralized TCEP aqueous solution 
at a final concentration of 500 μM at 4 °C: optimal molar concentration of EBB was 
estimated at 0.5 to 1.0 mM by LC-MS-based quantification of an intact peptide. 
Conversion yield to a crown analogue was maximum 80% (data not shown). EBB 
aqueous solution was added at a final concentration of 500 μM, and the mixture was 
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incubated at 4 °C for 3 hours in the dark. To inactivate the unreacted EBB, 
2-mercaptoethanol was added to the mixture at a final concentration of 5 mM, and 
further incubated at 4 °C for several minutes. The T7 phage particles were precipitated 
with a mixture of polyethylene glycol 6000 and sodium chloride to final concentrations 
of 5% (w/v) and 0.5 M, respectively. After centrifugation at 15,000 rpm for 10 minutes 
at 4 °C, the precipitate was suspended in an appreciate buffer. 
 
 
Figure S8. Western blotting against peptide-fused gp10. Trace amount of gp10 dimer was 
formed in the EBB-concentration dependent manner. 
 
Mass spectrometric analysis 
Mass spectrometric analysis was performed as described previously. The gel was 
stained with rapid stain CBB kit (Nacalai, Japan), and then the stained protein band was 
excised from the gel. The protein samples were reduced with 25 mM DTT at 55 °C for 
30 min, and then alkylated with 55 mM iodoacetamide at room temperature for 30 min 
in the dark. Digestion was carried out with modified trypsin (Trypsin Gold, Promega) or 
lysyl endopeptidase (Wako, Japan) at 37 °C overnight. The resulting peptides were 
analyzed using an Agilent 1100 HPLC system (Agilent Technologies) equipped with a 
C18 reverse-phase column (Hypersil GOLD, 2.1 × 100 mm, Thermo Fisher Scientific) 
connected to a LCQ-Fleet ion trap mass spectrometer. The peptides were separated 
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using a 0-50% gradient of acetonitrile containing 0.1% formic acid during 40 min at a 
flow rate of 300 μL per a minute, and then eluted peptides were directly sprayed into 
the mass spectrometer. The mass spectrometer was operated in the data-dependent 
mode and externally calibrated. Survey MS scans were acquired in the 100-2000 or 
400-2000 m/z range. Multiply charged ions of high intensity per scan were fragmented 
with CID in the ion trap. A dynamic exclusion window was applied within 30 seconds. 
All tandem mass spectra were collected using normalized collision energy of 40%. Data 
were acquired and analyzed with Xcalibur software v. 2.07 (Thermo Fisher). 
 
Biotinylation of Hsp90 
Porcine Hsp90 (a gift from Dr. Yasufumi Minami, Maebashi Institute of 
Technology, Japan) was biotinylated and purified with a kit (Biotin Labeling Kit –NH2, 
DOJINDO, Japan) according to the manufacturer’s instruction. The biotinylation of 
Hsp90 was confirmed by Western blotting (Fig. S9A). From densitometric 
quantification, it was estimated that approximately 9 molecules of biotin were 
conjugated to Hsp90 single molecule. Using FP assay (see FP assay section), we 
confirmed that the ATP-binding pocket of biotinylated-Hsp90 almost remained intact 
(see below; Fig. S9B). 
 
Figure S9. (A) Quantification of biotin conjugation to Hsp90. (B) Comparison of geldanamycin 
(GA)-binding avidity of Hsp90 and biotinylated-Hsp90 by FP assay. 
 
Biopanning 
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Biopanning was performed as described previously with minor modifications. 
Biotinylated-Hsp90 (20 pmol) was immobilized on streptavidin-coupled magnetic beads 
(FG beads, Tamagawa Seiki, Japan). For biopanning, approximately 1.0 × 1011 PFU of 
T7Select10 library (-S-G-G-G-X3-C-X7-C-X3; X represents any randomized amino acid) 
was modified via the 10BASEd-T. After the modification, T7 phage library was 
suspended in selection buffer (PBS supplemented with 1% (v/v) TritonX-100 and 1% 
(w/v) BSA). To remove non-specific binders (i.e. beads and streptavidin binders), the 
modified T7 phage library was pre-incubated with streptavidin-coupled FG beads for 2 
hours at 4 °C, and then the supernatant was further incubated with the 
Hsp90-immobilized beads for 12 hours. The latter beads were washed three times with 
each 200 μL of the selection buffer. Whole binding and washing process were 
performed using an automated machine (Target Angler 8, Tamagawa Seiki, Japan). 
Hsp90-bound phage was directly infected and amplified with E. coli BLT5403 strain. 
Stringent conditions were stepwisely applied to each round by shortening the binding 
time and by increasing the washing frequency. After the 6 rounds of the biopanning, 
randomly chosen T7 phage monoclones were subjected to DNA sequencing. 
 
Enzyme-linked immunosorbent assay (ELISA) 
ELISA was performed as described previously with minor modifications. Each 
wells of streptavidin-conjugated 96-well plate (Nunc Immobilizer Streptavidin F96, 
Thermo Scientific) were coated with blocking buffer (10 mM Tris-HCl, pH 7.5, 150 
mM NaCl, 0.05% (v/v) Tween-20, and 0.5% (w/v) BSA) at 4 °C overnight. After 
washing with Tris-buffed saline, biotinylated-Hsp90 (3 pmol) was immobilized on each 
well. Approximately 2.0 × 1010 PFU of T7 phage in TBST was applied to the well and 
incubated for 1 hour at 25 °C with shaking by using a maximizer (MBR-022UP, 
TAITEC, Japan). The plate was washed three times with Tris-buffered saline 
supplemented with 0.5% (v/v) TritonX-100, and then Hsp90-bound phage was 
incubated with T7 tail fiber monoclonal antibody (1:5,000 dilution, Merck Millipore) 
and anti-mouse IgG HRP-linked antibody (1:5,000 dilution, Cell Signaling). After 
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washing with the TBST, o-phenylenediamine dihydrochloride substrate (SigmaFast 
OPD, Sigma Aldrich) was added, and the absorbance was quantified using a microplate 
reader equipped with a 450 nm band-pass filter (Bio-Rad). 
 
Preparation of GST-fused Hsp90 domains and GST pull-down assay 
Three domains of human Hsp90α, N-terminal (NTD: 9-236), middle (MD: 272-617), 
and C-terminal domains (CTD: 629-732) were prepared as described previously. Briefly, 
pGEX-4T-3 vector encoding fragments of hsp90 gene (a gift from Dr. Franz-Ulrich 
Hartl, Max-Planck-Institute of Biochemistry, Germany) was introduced into E. coli 
BL21 (DE3) strain. Transformants were precultured overnight at 37 °C in 2 mL of LB 
medium supplemented with 100 μg/mL ampicillin, and then transferred to a 150 mL of 
fresh LB medium. After incubation for 4 hours at 37 °C, isopropyl 
β-D-1-thiogalactopyranoside was added at a final concentration of 0.2 mM, and the 
cells were further cultured for 20 hours at 20 °C. The cells were harvested, and 
suspended in ice-cold lysis buffer (50 mM Tris-HCl, pH 8, 300 mM NaCl, 1 mM EDTA, 
5 mM 2-mercaptoethanol, 0.5 % (w/v) Triton X-100, and 1 × complete protease 
inhibitor cocktail minus EDTA). After cells disruption by ultrasonication, the crude cell 
extract was cleared by centrifugation at 20,000 × g for 10 min at 4 °C. Using a 0.42 μm 
membrane filter, the extract was further cleared. Supernatant was incubated with 
glutathione sepharose 4B (GE Healthcare) for 2 hours at 4 °C. After several washing 
with the lysis buffer, the sepharose was suspended in stock buffer (20 mM Tris-HCl, pH 
8, and 50% (v/v) glycerol) and stored at -80 °C until use. 
For GST pull-down assay, 20 μL (50% slurry) of the GST-Hsp90-immobilized 
sepharose was suspended in 200 μL of binding buffer (50 mM Tris-HCl, pH7.5, 150 
mM NaCl, 0.05% (v/v) Tween-20, and 0.5% (w/v) BSA), and then 200 μL of the same 
buffer containing modified-T7 phage monoclone was added. After incubation for 2 
hours at 4 °C, the sepharose was washed three times with Tris-buffered saline 
supplemented with 0.5% (v/v) Triton X-100. GST-fusion proteins were eluted with 
elution buffer (50 mM HEPES-KOH, pH 7.4, 100 mM NaCl, 1 mM DTT, and 50 mM 
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reduced glutathione). After addition of 4 × sample buffer (250 mM Tris-HCl, pH 6.8, 
40% glycerol, 8% SDS, 20% 2-mercaptoethanol, and 0.008% bromophenol blue), the 
solution was incubated at 95 °C for 5 min. 
 
SDS-PAGE and Western blot analysis 
SDS-PAGE and Western blot analysis were performed as reported previously.  
Proteins were resolved by a 10% polyacrylamide gel. For Western blotting, proteins in 
the gel were transferred onto a polyvinylidene difuoride membrane (Bio-Rad). The blots 
were incubated with primary antibody, followed by incubation with anti-mouse IgG 
horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technology). 
After several washes, the blots were incubated with ECL plus reagent (GE Healthcare 
Life Sciences), and detected using ChemiDoc XRS+ (Bio-Rad). Image contrast and 
brightness were adjusted in Photoshop CS4 (Adobe). Primary antibodies: anti-T7 tag 
mouse monoclonal antibody (Merck Millipore) and anti-FLAG mouse monoclonal 
antibody (M2, Sigma Aldrich). Note that antigen (M-A-S-M-T-G-G-Q-Q-M-G) of the 
anti-T7 tag mouse monoclonal antibody is N-terminal region of gp10, which is a 
component of bacteriophage T7. 
 
Synthesis of Hsp90 NTD-binding crown molecule 
A peptide (H2N-R-S-W-C-R-K-S-R-K-N-S-G-G-G-L-V-W-C-F-OH) was 
synthesized and characterized by HiPep Laboratories (Japan). Purity of the peptide was 
estimated to be above 90%. For cyclization of EBB, the peptide was dissolved in 
phosphate buffer (10 mM phosphate-KOH, pH 7.4) at a final concentration of 100 μM, 
and then EBB (500 μM) and neutralized TCEP (500 μM) were added. The mixture was 
incubated overnight at 37 °C in the dark with shaking, and then lyophilized to reduce 
the solution volume. The lyophilizate was dissolved in 1% formic acid aqueous solution, 
and the crown molecule was purified with reverse-phase HPLC (Shimadzu, apan) 
equipped with a XTerra Prep MS C18 column (10 × 50 mm, Waters). The crown 
molecule was separated using a 0-100% linear gradient of acetonitrile containing 0.1% 
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trifluoroacetic acid during 12 min at a flow rate of 4 ml per a minute. The crown 
molecule was lyophilized and characterized by LC-MS (see below; Fig. S10). 
 
 
Figure S10.  MS spectra of synthetic peptide and Hsp90 NTD-binding crown molecule. 
 
Circular dichroism (CD) spectroscopy 
All compounds were dissolved in phosphate buffer (20 mM phosphate-KOH, pH 
7.2) at a final concentration of 50 μM. Circular dichroism spectra were recorded on a 
CD spectrometer (J-720W, JASCO, Japan) at 25 °C using a 0.2 cm path-length quartz 
cell (see below; Fig. S10). For reduction of disulfide-bond, TCEP was added at a final 
concentration of 1 mM.  
 
Isothermal titration calorimetry (ITC) 
ITC experiment was performed using MicroCal iTC200 (GE Healthcare). 
GST-tagged Hsp90 NTD was enriched using an ultrafiltration column (vivaspin column 
500 MWCO 10 kDa, GE Healthcare), and buffer was changed to phosphate buffer (20 
mM phosphate-KOH, pH 7.2, 50 mM NaCl, 1 mM TCEP). Protein concentration was 
determined by Bradford assay. For titration experiment, GST-Hsp90 NTD and 
compounds were diluted into 5 μM and 200 μM, respectively. Titrations were 
performed at 25°C. Injection parameters were the following: 2 μL volume, 4 sec 
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duration, 4 sec spacing, and 5 sec filter period. Reference power was set to 10 μcal/s. 
Data were analyzed with Origin software 7.0 (MicroCal). Curve fitting was performed 
using 1:1 interaction model. 
 
Fluorescence polarization (FP) assay 
Fluorescence polarization was measured using a HYBRID-3000ES (Photoscience, 
Japan) equipped with appropriate filters (Ex. 480 nm and Em. 535 nm). Instrument was 
operated in static mode. FITC-labeled geldanamycin (GA-FITC; 4 pmol, 20 nM) was 
incubated with various concentrations of GST-fused Hsp90 domains (NTD, MD, and 
CTD) in phosphate-buffered saline supplemented with 1 mM TCEP for 5 min at 30°C, 
and fluorescence polarization was measured. In the TCEP-containing solution, 
geldanamycin (GA) bound to Hsp90 in a short incubation time (ca., 2 min; data not 
shown). Klotz plot was generated by GraphPad Prism software 6.0 (GraphPad 
Software), and the sigmoid curve was fitted with non-linear least squares analysis for 
KD determination. For competition assay, various concentration of compounds were 
pre-incubated with GST-Hsp90 NTD (110 pmol, 550 nM) in phosphate-buffered saline 
supplemented with 1 mM TCEP for 10 min at room temperature. After addition of 
GA-FITC (4 pmol, 20 nM), the mixture was incubated for 5 min at 30 °C, and then 
fluorescence polarization was measured. GA-FITC and geldanamycin were purchased 
from Enzo Life Sciences (cat No. BML-EI361-0001) and StressMarq (cat No. 
SIH-111A/B), respectively.  Concentrations of GA-FITC and geldanamycin were 
determined by absorption coefficient at 336 nm. 
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■	 Concluding remarks 
 
Post-translational chemical modification of a genetically-encoded 
peptide library is an useful method for construction of hybrid molecule 
libraries possessing arbitrary functions (e.g., fluorescence). My study 
stands on this method. Current studies are employing the M13 phage 
display peptide library for the post-translational chemical modification, 
however the M13 library has intimate problems (e.g., sequence bias, 
infectivity loss associated with the modification etc.). To address the 
problem, a novel method for the construction of the hybrid molecule library 
is established in this study. By using the simple thioetherification reaction 
on bacteriophage T7-displayed peptides, three different characters of the 
hybrid molecule libraries have been constructed. Additionally, 
target-specific binders have been successfully obtained from these libraries. 
Among these, Hsp90-binding macrocycle has unique and interesting 
properties: the macrocycle specially binds to the N-terminal domain (NTD) 
of Hsp90, and can enhance binding of geldanamycin to the Hsp90 NTD. 
Though the binding affinity of the macrocycle is far enough (KD = 1.7 µM), 
a potential novel strategy of Hsp90 inhibition is presented. 
 
In the future, I will construct a novel peptide-based hybrid library and 
screen Hsp90-specific binders possessing druggable properties (i.e., higher 
target-binding affinity, higher specificity against a target, stronger 
proteolysis resistance, good cell penetrability, and good water solubility 
etc.). 
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